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ABSTRACT 
 
Purpose: To study the role of prolactin (PRL) and its antagonist, G129R, in 
HER2/Neu tumorigenesis. Specifically, to investigate the interaction between the 
oncogene HER2 and the PRL receptor (PRLR) signaling pathways for designing 
effective combinational therapeutics for breast cancer. 
Experimental Design: The combination effects of G129R and an anti-HER2 
antibody, Herceptin, were tested against HER2-overexpressing human breast cancer cell 
lines, T-47D and BT-474, using cell based assays and xenografts established in athymic 
mice.  Furthermore, four different bitransgenic mouse lines co-expressing the murine 
version of HER2 and PRL or G129R were generated.  The mammary tumor incidence, 
characterization of mammary gland development, and alteration of the molecular 
biomarkers in the mammary glands were investigated in these transgenic mice.   
Results:  It was demonstrated that PRL was able to activate HER2 in human 
breast cancer cells and the addition of G129R competitively inhibited the stimulatory 
effect of hPRL.  More importantly, G129R has synergistic/additive effects when used in 
combination with Herceptin in inhibiting HER2 activation.  Results further demonstrate 
that Herceptin and G129R displayed a synergistic inhibitory effect on MAPK 
phosphorylation.  Most importantly, the combinational treatment of Herceptin and 
G129R significantly inhibited the growth of xenografts in athymic mice.   
In the bitransgenic mouse study, it was found that co-expression of G129R in 
MMTV-neu female mice had little effect on overall HER2 tumor incidence due to the 
low expression levels of G129R.  Surprisingly, co-expression of low levels of PRL in 
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MMTV-neu female mice demonstrated a drastic reduction in tumor incidence in both 
hPRL/neu bitransgenic lines.  Suppressed expression of HER2, which lead to lower levels 
of MAPK activities and cyclin D1 expression were strong indications or evidence that 
support the significant change in the tumor incidence in these bitransgenic mice.
Conclusions:  PRL possesses a dual role in HER2/neu tumorigenesis: as a tumor 
promoter in transformed cells and as a tumor suppressor when expressed early before 
tumor formation.  To improve the outcome of breast cancer therapy, especially for HER2 
positive breast cancer, G129R may be used together with Herceptin as a combinational 
therapy.  On the other hand, data from the PRL bitransgenic mice suggests the possibility 
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Cancer is the second leading cause of death in the United States, behind heart 
disease.  Over one million people get cancer each year.  Approximately one out of every 
two American men and one out of every three American women will have some type of 
cancer at some point during their lifetime.  Cancer is defined as a group of diseases that 
are characterized by the uncontrollable growth and spread of abnormal cells (Weinberg, 
1996).  Normal cells grow, divide and die in an orderly fashion, whereas, cancer cells are 
immortal and continue to grow and divide.  Cancer cells can also travel to other parts of 
the body by spreading through the bloodstream and lymphatic system where they begin 
to grow and replace normal tissue, allowing the cancer to metastasize. 
According to the American Cancer Society, cancer cells develop because of 
damage to DNA.  DNA can become damaged many different ways such as exposure to 
something in the environment.  Most of the time the body is able to repair its damaged 
DNA; however, in cancer cells, the damaged DNA does not get repaired.  People can also 
inherit damaged DNA, which also accounts for inherited cancers.   
The exact cause of cancer is unknown. However, we do know that certain genes 
contain instructions for controlling when cells grow, divide, and die.  A proto-oncogene 
is a normal gene whose protein product has the capacity to induce cellular transformation 
given it sustains some genetic insult. An oncogene is a gene that has sustained some 
genetic damage and, therefore, produces a protein capable of cellular
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transformation.  Genes that slow down cell division, or cause cells to die, are called 
tumor suppressor genes.  It is known that cancers can be caused by DNA mutations that 
"turn on" oncogenes or "turn off" tumor suppressor genes. 
In Hanahan and Weinberg’s paper, The Hallmark of Cancer, they proposed that 
most if not all types of cancers acquire six alterations in their cell physiology.  These 
different acquired capabilities of cancer are: 1. self-sufficiency in growth signals, 2. 
insensitivity to growth-inhibitory (anti-growth) signals, 3. evasion of programmed cell 
death (apoptosis), 4. limitless replicative potential, 5. sustained angiogenesis, and 6. 
tissue invasion and metastasis.  Over the years, three more provisions have been added to 
this list including: stem cell source of tumor, energetic requirements for the tumor, and 
lastly an immune system evasion. 
Different types of cancer can behave very differently.  They grow at different 
rates and respond to different treatment.  The major types of treatment for cancer are 
surgery, radiation, chemotherapy, hormone therapy and immunotherapy.  People with 
cancer need treatment that is targeted for their particular type of cancer, location of 
cancer, progression of the disease and the health status of the patient. Cancer treatments 
are designed to either directly kill or remove the cancer cells or to lead to their eventual 
death by depriving them of signals needed for cell division. Other treatments work by 
stimulating the body's own defenses. 
Often the first line of treatment for many solid tumors is surgery.  Surgery may be 
sufficient to cure the patient by removing all cancerous cells when the cancer is detected 
at an early stage.  Another cancer treatment that may be used in conjunction with surgery 
is radiation. The goal of radiation is to kill the cancer cells directly by damaging them 
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with high energy beams.  Chemotherapy is a wide array of drugs used to kill cancer cells. 
Chemotherapy drugs work by damaging the dividing cancer cells and preventing their 
further reproduction. Hormone therapies are drugs that are designed to prevent cancer 
cell growth by preventing the cells from receiving signals necessary for their continued 
growth and division.  Lastly, immunotherapy involves the use of naturally occurring, 
normal proteins to stimulate the bodies own defenses against cancer. 
According to the American Cancer Society, another class of drugs that is 
relatively new in the treatment of cancer is specific inhibitors.  They work by targeting 
specific proteins and processes that are limited primarily to cancer cells or those that are 
more prevalent in cancer cells. Inhibition of these processes prevents cancer cell growth 
and division. Antibodies are another treatment that targets cancer cells.  Antibodies used 
in the treatment of cancer have been manufactured for use as drugs. They may work by 
several different mechanisms, either depriving the cancer cells of necessary signals or 
causing the direct death of the cells. Antibodies may be thought of as a type of specific 
inhibitor due to their specificity.  Finally, vaccines are another type of cancer treatment.  
Cancer vaccines stimulate the body's defenses against cancer.  By administering proteins 
found on or produced by cancer cells, the treatment increases the response of the body 
against the cancer cells. 
Breast Cancer 
According to the American Cancer Society, breast cancer is the most common 
cancer among women, other than skin cancer. It is the second leading cause of cancer 
death in women, after lung cancer.  In 2006, about 212,920 women in the United States 
will be found to have invasive breast cancer.  About 40,970 women will die from the 
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disease this year.  The chance of a woman having invasive breast cancer during her life is 
about 1 in 8 and the chance of dying from breast cancer is about 1 in 33.  Breast cancer 
death rates are declining due to earlier detection and improved treatment. 
Breast cancer is a heterogeneous disease arising from multiple genetic changes in 
oncogenes and tumor suppressor genes with pivotal roles in the homeostatic control of 
mammary epithelial cell proliferation, differentiation and death (Sutherland and 
Musgrove, 2002).  The cause of breast cancer is not clear, and most likely cannot be 
triggered by a single etiologic agent.  Rather the genesis of breast cancer like many other 
cancers results from the stepwise accumulation of mutations in genes (Chodosh, 2002).  
Although many risk factors may increase the chance of developing breast cancer, it is not 
yet known exactly how some of these risk factors cause cells to become cancerous.   Like 
improbable partners at a dance, the normal development of the breast goes hand in hand 
with its susceptibility to cancer (Chodosh, 2002). 
A study of population-attributable risks has estimated that at least 45% to 55% of 
breast cancer cases in the United States may be explained by the following factors: 
advanced age at the time of the first full-term pregnancy, nulliparity, family history of 
breast cancer, higher socioeconomic status, earlier age at menarche, and prior benign 
breast disease (Russo and Russo, 2004).  Only 10% of human breast cancers are 
considered to be the result of inherited mutations of the tumor suppressor genes, BRCA1 
or BRCA2, while the remaining 90% of cases are related to the disruption of biochemical 
pathways involving growth factors and hormones and their receptors; such as the 
estrogen receptor, the progesterone receptor and more recently the c-ErbB-2 receptor 
(Yamauchi, T. et al., 2000).  The most common types of breast cancer are carcinoma in 
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situ, ductal or lobular carcinoma in situ, and infiltrative ductal or lobular carcinoma.  The 
cancer is confined to either the ducts or the lobules if it has not gone into the fatty tissues 
in the breast nor spread to other organs in the body. 
For decades, the primary therapy for women with breast cancer has been surgery, 
radiation or a combination of both (Miller and Langdon, 1997; Forrest, 1997; Roses, 
1999).  Hormone therapy and chemotherapy are adjuvant treatments for breast cancer 
after surgery.  Common hormone therapy for breast cancer is an anti-estrogen treatment 
such as tamoxifen.  Tamoxifen blocks the actions of the hormone estrogen since certain 
types of breast cancer require estrogen to grow.  It has been reported that tamoxifen is 
also effective as a preventive agent in reducing the incidence of breast cancer up to 45% 
in a group of healthy women over age 35 who have a higher-than-normal risk of getting 
the disease (Marshall, 1998).  However, the heterogeneous nature of breast cancer 
translates to low response rate in many therapies.  It has been reported that approximately 
half of the breast cancers are estrogen receptor (ER) negative, which partly explains why 
tamoxifen is not universally effective (Forrest, 1997).   
It is obvious that the scope of the search for anti-breast cancer drugs should be 
expanded in order to effectively control tumor growth and/or recurrence.  Also, 
combinations of proven effective methods, especially those intended to target different 
pathways or mechanisms should be further investigated. 
PRL’s pathogenic role in mammary cancer 
Prolactin (PRL) is the hormone intimately involved in puberty and pregnancy, 
acting both as a mitogen and a differentiation agent (Horseman, 1995; Vonderhaar, 1998; 
Clevenger et al., 2002).  The importance of PRL in pathological conditions such as 
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mammary tumor growth in women is well established.  Several lines of evidence support 
the involvement of PRL in breast cancer formation.  PRL expression has been detected in 
human mammary tumors and human mammary tumor cell lines can produce PRL (Ben-
Jonathon et al., 1996) suggesting that PRL is produced locally, thus serving as an 
autocrine and paracrine growth factor within the mammary glands.  Second, transgenic 
mice expressing lactogenic hormones such as PRL have a very high incidence of breast 
cancer (Rose-Hellekant et al., 2003; Wennbo et al., 1997).  Third, the level of expression 
of PRL receptor is greatly elevated in human breast cancer cells compared to normal 
(Reynolds et al., 1997), and in surgically removed breast cancer tissues compared to its 
normal surrounding tissues as seen in Fig. 1 (Touraine et al., 1998).  Fourth, PRLR 
antagonists can inhibit the growth of established breast cancer cells in vitro (Fuh and 
Wells, 1995) and in xenografts in nude mice (Chen et al., 1999; 2002).  These findings 
suggest that hPRL is an autocrine/paracrine growth factor that plays an important role in 
breast cancer development and progression.   Since both PRL and PRLR are expressed 
widely in breast cancer, this provides a strong argument in support of using targeted 
inhibition of signaling via the PRLR capable of blocking or inactivating the hPRLR 
locally at the level of the breast cancer cell as therapeutics or chemopreventive agents. 
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          (Touraine et al., J Clin Endo Metab 1998 83: 667-74) 
 
Fig. 1. PRLR expression level in breast cancer tissue compared to normal tissue.  In 
surgically removed breast cancer tissues PRLR expression level is greatly elevated 
compared to its normal surrounding tissues. 
 
Prolactin gene, mRNA and protein 
PRL is a 23-kDa single chain polypeptide hormone that is closely related to 
growth hormone (GH).  PRL is synthesized in the anterior pituitary by hormone 
producing cells called lactotrophs and are involved in the growth and development of the 
mammary gland (Clevenger et al., 1995).  It is also synthesized and secreted by a broad 
range of other cells in the body, most prominently various immune cells, the brain and 
the deciduas of the pregnant uterus.  In addition to its role as a neuroendocrine hormone, 
PRL is also produced by the breast epithelium as an autocrine/paracrine growth factor 
 8
and functions as a cytokine (Clevenger et al., 1995, 2003; Ginsburg and Vonderhaar, 
1995; Ben-Jonathon et al., 2002). 
The hPRL gene is located on chromosome 6 and is composed of 5 exons, which 
are separated by 4 large introns that together measure approximately 10kb (Fig. 2).  
Human PRL's 1 kilobase mature mRNA codes for 227 amino acids that are composed of 
the signal peptide containing 28 amino acids and the mature protein containing 199 
amino acids with a molecular weight of 23 kDa.  The signal peptide is a short chain 
peptide that directs the post-translational transport of prolactin.  Human PRL contains 3 
disulfide bonds between amino acids 4-11, 58-174 and 191-199.  This creates small loops 
at amino and carboxy terminal ends and a large loop in the middle of the molecule.  
There is high homology (80-90% between hPRL and rPRL) in the 5' flanking region of 
the gene between human, rat and bovine indicating conserved regulatory element in the 
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Fig. 2.  Prolactin gene, mRNA and protein.  Prolactin gene consists of 5 exons which, 
when transcribed to the mRNA, will contain 5' and 3' untranslated region together with 
the signal and protein sequence.  The prolactin protein contains a 28 amino acid signal 
peptide and 199 PRL amino acids. 
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Multiple isoforms of PRLR 
In order for PRL to have an effect on a cell target, PRL must first bind to a 
specific membrane receptor, prolactin receptor (PRLR), which belongs to the cytokine 
receptor superfamily.  The PRLR is composed of at least three separate regions: an 
extracellular region with 5 cysteines that contain the prolactin binding site, a single 
transmembrane region and a distinct intracellular region that lacks intrinsic catalytic 
activity.   
The hPRL receptor gene can create multiple isoforms resulting from alternative 
splicing as seen in Fig. 3.  These different PRLR isoforms are referred to as short (∆S1), 
intermediate or long isoforms in accordance with their sizes.  While three PRLR isoforms 
have been characterized in the rat, studies have suggested the existence of several human 
isoforms in breast carcinoma species and normal tissues (Kline et al., 1999).  Both the 
intermediate and the long form of the PRLR contain an identical extracellular domain 
(ECD), which is critical for engagement with its ligand.  Although the affinity for the 
intermediate hPRLR is similar to that of the long isoform, the intermediate isoform is 
truncated in its C-terminus as a consequence of an out-of-frame splicing event.  The 
intermediate isoforms is capable of Jak2 activation, but is incapable of activating the Fyn 
tyrosine kinase.  The short, ∆S1, isoform shares a similar intracellular portion of the 
hPRLR with the long isoform, but is missing the entire S1 domain of the extracellular 
portion of the receptor (Fig 3) causing the affinity of the ∆S1 isoform to be reduced by 
approximately 7-fold (Clevenger et al., 2003).  The function within the mammary gland 
of the various PRLR isoforms remains a difficult question to address, as covariable 
expression of each of the PRLR isoforms is observed within mammary tissues and cell 
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lines (Clevenger et al., 2003).  Multiple isoforms of PRLR exist that differ in their 




























Fig. 3. Schematic representation of multiple isoforms of hPRL receptor. Different 
PRLR isoforms are referred to as short (∆S1), intermediate or long.   
 
Mechanism of PRL signaling 
In order for the cell to respond to PRL, PRL has to bind to its receptor.  Receptor 
dimerization for PRL has been shown to involve two different regions of the ligands 
referred to as binding sites I and II (Fig 4). PRL first binds to one PRLR via binding site I 
to form an inactive, intermediate 1:1 complex. PRL bound in this complex then binds to a 
second PRLR molecule via the site II binding site to create a 1:2 PRL-PRLR complex.  
Upon binding of the extracellular PRL to the membrane bound homodimer receptor, the 
ligand/receptor complex dimerizes and activates a series of signaling cascades, triggered 
by phosphorylation, that can lead to cell proliferation (Ihle, 1996).  However if the 
hormone concentration is too high, the hormone and the receptor will only form a 
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heterodimeric complex, possibly acting as an antagonist because it blocks signal 
transduction.  
 
       (Fuh G. et al., JBC 1993 vol. 268, pp. 5376-81) 
 
Fig. 4. Sequential dimerization model of the hPRLR by hPRL.  At low 
concentrations, hPRL binds first at site1 and then site 2.  At high concentrations, hPRL 
saturates the receptor through site 1 interaction and acts as an antagonist by preventing 
receptor dimerization. 
 
Since, the PRLR is devoid of intrinsic tyrosine kinase activity, it relies on other 
kinases to phosphorylate the intracytoplasmic portion of the receptor and signal 
transduction molecules involved in PRL signaling events within the cell (Fig. 5).  The 
function of the PRLR is mediated, at least in part, by two families of signaling molecules: 
Janus kinases (Jak) and signal transducers and activators of transcription (STATs).  Jak2 
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is constitutively associated with the PRLR (Lebrun et al., 1994; Goupille et al., 1997) and 
autophosphorylation of Jak2 occurs upon PRL binding to the PRLR.  Phosphorylated 
tyrosine residues on the intracytoplasmic domain of the PRLR recruit and induce 
phosphorylation of cytoplasmic transcription factors, mainly STAT-1, STAT-3, and 
STAT-5 (Vonderhaar, 1999; DaSilva et al., 1996).  STAT proteins are important 
transcriptional regulators in the cell and have two main functions that include signal 
transduction in the cytoplasm and activation of transcription in the nucleus (Cataldo et 
al., 2000).  STAT proteins can either stimulate or inhibit gene transcription, depending on 
promoter context (Brockman et al., 2002).  The PRLR utilizes the Jak-STAT pathway as 
its main signaling cascade (Ben-Jonathon et al., 2002).  
In addition to the Jak/STAT pathway, PRL has been shown to utilize other 
pathways in some systems.  By phosphorylation of the PRLR at the carboxy-terminal 
tyrosinases, Jak2 may enable the association of the signal adaptor protein SHC with the 
PRLR, which in turn activates the Shc/Grb2/Vav/Sos/Ras/Rac/Raf/MEK/MAPK 
signaling cascade (Clevenger et al., 1998).  A variety of growth factors and cytokines 
mediate proliferation by activating the ras-MAP kinase pathway of signal transduction 
(Vonderhaar, 1999).  PRL also can activate the JNK group of MAPKs, which is 
important for its mitogenic signaling and suppression of apoptosis in some cell types 
(Brockman et al., 2002).   The mitogen-activated protein kinase (MAPK) pathway 
controls the growth and survival of a broad spectrum of human tumors (Sebolt-Leopold 
and Herrera, 2004).   
Both the long and the short form of the PRL receptor are able to activate MAP 
kinase, with the activity reaching a peak within 5 min of PRL treatment (Das & 
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Vonderhaar, 1995).  Both Jak-STAT and MAPK pathways are activated upon PRL 
treatment in several breast tumor cell lines, and may act in parallel, or may converge at 
some point in the signaling pathway (Brockman et al., 2002). 
 
 
       
       (Bole-Feysot C. et al., Endo Rev 1998 19(3) : 225-268) 
 
Fig. 5.  Schematic representation of the PRLR signaling pathways. The major signal 
transduction pathway of the long PRLR isoforms is the JAK-STAT cascade.  For the 
short isoforms, however, many components are still unknown except that it signals 




Significant inhibition of tumor progression has been achieved in rodents by 
removing their pituitary gland or by inhibiting the release of PRL from the pituitary using 
a dopamine agonist, bromocriptine.  Bromocriptine has been considered minimally 
effective or ineffective in treating breast cancer thus causing PRL to be disregarded as a 
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major contributing factor in breast cancer progression (Bonneterre et al., 1988; Anderson 
et al., 1993; McMurray et al., 1995).  Failure of treatments blocking pituitary PRL 
production, are now thought to be due to extrapituitary PRL production by many tissues 
throughout the body, including local production of PRL within the mammary gland.  
Removal of the pituitary gland reportedly reduces the circulating levels of hPRL by 20-
70% whereas other pituitary hormones became undetectable, suggesting therapeutics 
should be designed that directly antagonize hPRLR signaling rather than its release.   
Anti-hPRL antibodies and anti-sense RNA directed against the hPRL gene have 
been used to successfully inhibit T-47Dco cell proliferation in vitro, as have antibodies 
against hPRLR in multiple breast cancer cell lines.  These findings validate that PRLR 
antagonists may be used to counteract the pro-tumor action of PRLR ligands by acting at 
the level of receptor activator as shown in Fig. 7 (Goffin et al., 2003).   
It has previously been demonstrated that the third α-helix of GH is important for 
its growth promoting activity (Chen et al., 1990; 1991; 1994; 1995).  It was also 
demonstrated that Gly 119 of bGH (Chen et al., 1991) or Gly 120 of hGH (Chen et al., 
1994) plays a critical structural role in growth enhancement.  By substituting one, single 
amino acid with one that contains a bulky side chain such as Arg, Lys, Trp, or Pro at 
position 120 of hGH results in a GH antagonist.  This antagonist prevented receptor 
dimerization and disrupted intracellular signal transduction.  It was demonstrated that a 
single amino acid substitution at position 129 of hPRL from Gly to Arg (G129R) results 
in an hPRL antagonist (Chen et al., 1999; Goffin et al., 1996).  Steric hindrance prevents 
binding to the second receptor in the dimmer and hence they act as hormone antagonists 
as demonstrated in Fig. 6 (Goffin & Kelly, 1997).    
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     (Chen et al., Clin Can Res 1999 5: 3583-93) 
Fig. 6. Schematic representation of the wild-type hPRL (left) and the hPRLR 
antagonist (G129R, right) interaction with the PRLR.  The four helical regions of the 
ligand are labeled as I, II, III, and IV.  The Gly to Arg substitution is in the third alpha-
helix and blocks functional dimerization and signal transduction of the receptors. 
 
It has been shown that G129R has a receptor binding affinity similar to that of 
hPRL demonstrating that G129R has a competitive receptor antagonistic action.  By 
using cell proliferation assays it was shown that G129R exerts inhibitory effects on breast 
cancer cell proliferation (Chen et al., 1999).  G129R exerted its inhibitory effects through 
apoptosis in four hPRLR positive breast cancer cell lines (T-47D, MCF-7, MDA-MB-134 
and BT-474) in a dose dependent manner as determined by the Terminal 
deoxynucleotidyl transferase-mediated dUTP Nick-End Labeling (TUNEL) assay (Chen 
et al., 1999).  To understand the molecular basis of how the antagonist induced apoptosis, 
differential gene expression profile using subtractive PCR combined with cDNA 
microarray techniques of four human breast cancer cell lines were tested following 
treatment with hPRL and G129R (Beck et al., 2001; 2002).  The anti-apoptotic gene, bcl-
2, was differentially expressed in the PRL treated breast cancer cell lines, but was not 
expressed in the G129R treated breast cancer cell lines (Beck et al., 2001; 2002).  To 
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confirm these results, real-time reverse transcription polymerase chain reaction (RT-
PCR) was used to measure bax and bcl-2 gene expression in eleven breast cancer cell 
lines after hPRL or G129R treatment.  It was shown that Bcl-2 was up-regulated in 
response to hPRL and was competitively inhibited by G129R in the majority of the cell 
lines tested (Pierce & Chen, 2004).  This suggested that hPRL might act as a survival 
factor by inducing genes involved in suppression of apoptosis further strengthening 
G129R's potential anti-apoptotic, therapeutic role in breast cancer therapy. 
The phosphorylation status of the oncogenes STAT-3 and STAT-5 were 
investigated since STAT-3 and STAT-5 have been shown to play a role in signal 
transduction of mammary gland development and human breast cancer cells (Li, 1997).  
The inhibitory effects of G129R on human breast cancer cells are mediated, at least in 
part, through the inhibition of JAK2/STAT phosphorylation, in particular, oncogene 
STAT-3 phosphorylation (Cataldo et al., 2000).  hPRL was able to activate both STAT-3 
and STAT-5 and G129R was capable of inhibiting STAT-3 and STAT-5 tyrosine 
phosphorylation activation in human breast cancer cells when induced by hPRL (Cataldo 
et al., 2000).  These data further strengthen our speculation that activation of the 
JAK2/STAT pathway is an hPRLR specific event.   
G129R's anti-tumor effects were also tested in nude mice using two PRLR 
positive (T-47D and MCF-7) human breast cancer xenografts (Chen et al., 2001).  Daily 
treatment of PRL exhibited enhanced tumor growth versus the control mice, whereas the 
treatment with G129R, inhibited tumor growth by approximately 50% compared to the 
control (Chen et al., 2001).   In conclusion, both in vitro and in vivo results demonstrate 
that G129R has potential as a novel anti-breast cancer agent.  G129R has been 
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demonstrated to antagonize every aspect of hPRL-induced effects analyzed in various 
breast cancer cell lines (Llovera et al., 2000) including inhibition of hPRL-activated 
JAK/STAT and MAPK pathways. 
 
   (Goffin et al., Endocr Rev 2005 3: 400-22) 
 
Fig. 7. Endocrine and autocrine/paracrine ligands of the PRLR.  Dopamine and 
somatostatin are inhibitors of pituitary synthesis, but G129R, a PRLR antagonist, can be 
used as a negative regulator of extrapituitary PRL production. 
 
ErbB2/HER2/neu oncogene 
 The name ErbB-2, neu (rat homolog), or HER2 is derived from “Human 
Epidermal growth factor Receptor” as it features substantial homology with EGFR (Ross 
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et al., 2001).  In Fig. 8, HER2/ErbB-2 is one of four members in a family of tyrosine 
kinase growth factor receptors that also include HER1/EGFR/ErbB-1, HER3/ErbB-3, and 
HER4/ErbB-4 (Watson, 2002).  These four receptors form a complex array of 
homodimers and heterodimers in response to ligand binding, with HER2 serving as the 
preferred heterodimer binding partner (Watson, 2002).  Heterodimerization of HER2 with 
other ErbB family members initiated through ligand binding leads to 
autophosphorylation, transphosphorylation, and finally activation of the receptor dimer as 
a kinase for cytoplasmic substrate (Ross et al., 2001; Stern, 2000).  This horizontal 
network of interactions is crucial to the ErbB signaling pathway, since HER3 is devoid of 
intrinsic kinase activity and HER2 is a ligand-less receptor.  Therefore, in isolation 
neither HER3 nor HER2 have the capacity to initiate down-stream signaling, and thus 
requires co-recruitment with another ErbB-member to be transactivated (Carraway and 
Cantley, 1994).   An exception to the rule is that HER2 can spontaneously form active 
ligand-less homodimers in cells overexpressing HER2 (Baselga et al., 1998) ErbB 
pathways become activated by several mechanisms including overproduction of ligands, 





        (Tzahar and Yarden. Biochim Biophys Acta. 1998; 1377:M25) 
 
Fig. 8. Four members of the ErbB family of receptor tyrosine kinases: HER1, HER2, 
HER3, and HER4.  HER2 has no known ligand and HER3 lacks tyrosine kinase activity. 
There are numerous ErbB-specific ligands that include: transforming growth factor-α 
(TGF-α), amphiregulin (AR), epidermal growth factor (EGF), heparin-binding EGF (HB-
EGF), betacellulin (β-CEL), epiregulin (EPR) and neuregulins (NRG). 
 
HER2/neu’s role in mammary tumorigenesis 
Overexpression of the HER2 protein occurs in 25%-30% of human breast cancers 
and leads to a particularly aggressive form of the disease (Ciardiello and Tortora, 2001; 
Miles, 2001; Shawver et al., 2002; Vogel et al., 2002).  Women whose cancers 
overexpress HER2/neu have a relatively poor prognosis with a median survival of 3 
years, compared with 6–7 years for HER2-negative cases (Slamon et al., 1987; Chazin et 
al., 1992). HER2 overexpression has also been associated with estrogen and progesterone 
receptor negativity.   
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Given the close correlation between neu overexpression and mammary 
carcinogenesis, a number of laboratories have been interested in directly testing the 
tumorigenic potential of the neu oncogene in the mammary epithelium of transgenic 
mice.  Several lines of transgenic mice were generated carrying the activated rat neu 
oncogene under the transcriptional control of the mouse mammary tumor virus (MMTV) 
promoter/enhancer (Guy et al., 1992).  The HER2/Neu transgenic mouse is an important 
preclinical model because it recapitulates the development of HER2/Neu positive human 
breast cancer, characterized by over-expression of HER2/Neu antigen and aggressiveness 
(Ren, 2004) and results in the rapid development of multifocal mammary tumors that 
metastasize with high frequency (Davies et al., 1999).  Overexpression of neu in the 
mammary tumors was also associated with elevated neu intrinsic tyrosine kinase activity 
(Guy et al., 1992). 
Therapeutics targeting HER2/neu 
 One successful anti-receptor strategy has been the development of trastuzumab 
(Herceptin; Genetech, San Francisco, CA).  Herceptin is a recombinant humanized 
monoclonal antibody directed at the extracellular domain of HER2, which is designed to 
block and neutralize HER2 protein (Fendly et al., 1990).  Herceptin exerts its antitumor 
activity by several mechanisms including receptor down modulation, prevention of 
cleavage of the receptor’s extracellular domain (which leads to receptor constitutive 
activation), and by recruiting host’s immune effector cells (Baselga et al., 1998).  
Herceptin was also shown to induce regression of HER2 overexpressing breast cancers, 
thus validating HER2 as a therapeutic target within the HER (erbB) network (Moulder et 
al., 2001).  Herceptin has shown clinical activity against HER2 overexpressing breast 
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tumors and has been recently approved for clinical use given alone or in combination 
with chemotherapy.  However, not all women respond to these treatments, and the precise 
role that HER2 plays in the etiology of breast cancer remains poorly understood.  A 
critical question that remains unknown is whether HER2 is involved directly in the 
initiation of breast cancer or rather instead only helps to drive cancer progression 
(Watson, 2002). 
 
         (http://www.herceptin.com/herceptin/professional/about/moa.jsp#references) 
Fig. 9. Anti-HER2/neu monoclonal antibody, Herceptin. Herceptin is a recombinant 
humanized monoclonal antibody directed against the extracellular domain of the HER2 
tyrosine kinase receptor. 
 
Crosstalk between PRL and HER2/neu  
Recent research in breast cancer is identifying many significant differences 
between cell lines derived from different breast tumors. These breast cancer cell lines 
have recently been found to differ not only in their response to treatment, but vary greatly 
in their utilization of different death/survival pathways. Researchers are also uncovering 
crosstalk between various cell surface receptor pathways, and discoveries such as the 
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interaction between hPRL and the ErbB-2 receptor (Yamauchi, 2000).  This emphasizes 
the importance of expanding our knowledge and better defining the role of prolactin in 
human breast cancer. 
It is believed that constitutive phosphorylation of HER2/neu contributes to poor 
prognosis and unsatisfactory clinical response of HER2/neu positive breast cancer to anti-
HER2/neu monoclonal antibody therapy.  Despite encouraging reports regarding 
Herceptin clinical trial results, there was only a 20 to 30% overall response rate 
(Cobleigh et al., 1999; Miles, 2001; Slamon et al., 2001; Vogel et al., 2002).   Herceptin's 
ineffectiveness in many cases many be explained by evidence that hPRL constitutively 
activates oncogene HER2/neu through activation of JAK2 kinase (Yamauchi et al., 
2000).  Yamauchi et al. revealed that autocrine secretion of hPRL led to constitutive 
tyrosine phosphorylation of HER2/neu via Jak2 by providing docking sites for Grb2 and 
stimulating the Ras-MAP kinase cascade.  This cross-phosphorylation leads to enhanced 
cellular proliferation, additive to the intrinsic tyrosine kinase activity of ErbB-2, in 
human breast cancer cell lines (Fig. 10). 
According to Yaumauchi et al., immunohistochemical analyses revealed that 76 
human breast carcinoma tissues examined, 29% were positive for HER2/neu, 95% 
positive for PRL and 100% were positive for PRLR.  Together, 28% breast cancers 
displayed HER2/neu and PRL immunoreactivity.  This expression of HER2/neu or PRL 
was then correlated to that of PCNA, a marker of proliferative activity.  The mean 
positive percentage of PCNA was 52.4% in the group of patients with both HER2/neu 
and PRL-positive compared to 38.3% (p<0.013) in the patients with PRL-positive, 
HER2/neu-negative breast cancer.  These data suggest that breast cancers with HER2/neu 
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overexpression have higher proliferative and metastatic activity in the presence of 
autocrine/paracrine secretion of PRL.  The same authors further demonstrated that the 
autocrine secretion of PRL in breast cancer cells stimulates tyrosine phosphorylation of 
HER2/neu via activation of Jak2 kinase, which is one of the main reasons that HER2/neu 
is constitutively activated in breast cancer.    
Since the oncogenic potential of HER2/neu appears to depend on the state of 
tyrosine phosphorylation (D’souza and Taylor-Papadimitriou, 1994; Clark et al., 1996), 
Herceptin, which is designed to bind to the extracellular portion of HER2/neu (thus 
preventing it from receiving further stimulation), may not be effective in stopping the 
signal transduction from already the constitutively phosphorylated cytoplasmic tail of 
HER2/neu protein.  Therefore, in order to effectively reduce the oncogenic effects of 
HER2/neu, inhibition of PRL pathway using hPRL antagonist should be considered.   
Physiological events in vivo are regulated by a complex interplay of signals, 
including multiple growth factors and hormones (Gutzman et al., 2005).  Although much 
is known about signaling by cytokines and growth factors, relatively little is known about 




























































































Fig. 10. Schematic representation of the potential cross-talk between hPRL and 
HER2/neu. Proposed signaling cascade of hPRLR and ErbB2 in the presence of 
autocrine secreted PRL.  
 
PRLR and ER  
The importance of mammogenic hormones such as PRL and 17β-estradiol (E2) in 
normal mammary growth and development has led to exploring their roles in the 
development and progression of breast cancer.  Estrogen receptors and PRL receptors 
were found to be co-expressed and cross regulated in mammary tumor cell lines and in 
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primary breast cancers (Bonneterre et al., 1990; Murphy et al., 1984; Ormandy et al., 
1997).  It has been reported that sex steroid hormones and PRL interact synergistically to 
control cancerous growth within the mammary gland (Ormandy et al., 1997).  It has also 
been shown that endogenous PRL increases ERα levels and their responsiveness of cells 
to estrogens in vitro, suggesting that PRL amplifies the effects of estrogen (Gutzman JH, 
et al., 2004).   
There is a hormonal crosstalk between PRL and E2 which is initiated primarily by 
a rise in levels of phosphorylated ERK1/2 that occurs relatively late after exposure to 
both hormones and stimulates c-fos promoter activity (Gutzman et al., 2005).  This 
receptor cross-regulation may provide a general mechanism allowing synergy among 
estrogens, progesterone, and PRL in many target tissues; which suggest that the use of 
antisteroid hormone therapy in breast cancer may be attacking only half of the synergistic 
equation (Ormandy CJ et al., 1997). 
PRLR and EGFR  
Recent studies suggest that PRL, growth hormone (GH) and other cytokines may 
use multiple mechanisms to crosstalk with EGFR and/or ErbB-2 (Johnson et al., 1997; 
Yamauchi et al., 1997, 1998, 2000; Qiu et al., 1998; Quijano and Sheffield, 1998; Kim et 
al., 1999; Maus et al., 1999; Badache and Hynes, 2001; Huang et al., 2003).  It has been 
demonstrated that GH induces tyrosine-phosphorylation without the activation of EGFR 
kinase activity (Yamauchi et al., 1997; Kim et al.  1999).  In several breast cancer cell 
lines, it has been demonstrated that hPRL and EGF synergize to enhance cell motility and 
in activating SHC and ERK signaling, suggesting a potentially important context-specific 
elements of crosstalk between these two factors (Huang et al.,  2006).  PRL has also been 
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shown to induce threonine phosphorylation of the EGFR in normal mammary epithelial 
cells (Fenton and Sheffield, 1993; Johnson et al., 1996; Quijano and Sheffield, 1998).  
Whereas, autocrine secretion of PRL is also able to stimulate tyrosine phosphorylation of 
ErbB-2 by Jak2 and stimulate the Ras-MAP kinase cascade (Yamauchi et al., 2000).  The 
identification of this novel cross-talk between growth factor receptors and cytokine 
receptors may provide new targets for therapeutics and preventative intervention. 
ER and EGFR 
The EGFR family proteins are receptor tyrosine kinases that, when bound to 
ligand through the extracellular ligand binding domain, result in receptor dimerization, 
kinase activation, and transphosphorylation on C-terminal regulatory tyrosinases.  
Tumors typically depend on only one of these pathways and may overexpress either 
estrogen receptor (ER) or EGF receptor (EGFR) and related family members.  
Intracellular mediators of these growth-stimulatory pathways are not completely defined, 
but one potential common mediator of EGF and ER signaling is the transcription factor 
signal transducer and activator of transcription 5 (STAT-5) (Boerner et al., 2005).  
Estrogen was shown to negatively regulate EGF-mediated tyrosine phosphorylation of 
STAT5, in human EGF family receptor-overexpressing breast cancer cells (Boerner et 
al., 2005).   
Rational therapeutic combinations for breast cancer 
Synergy, as it applies to drug-drug interactions, is defined as a combination of 
two or more drugs which achieves a therapeutic effect greater than that expected by the 
simple addition of the effects of the component drugs (Pegram et al., 1999).  Such 
synergistic interactions between drugs may improve therapeutic results in cancer 
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treatment if the synergism is specific for tumor cells (Chou and Talalay, 1984).  Analysis 
of the nature of the interaction between two drugs (synergism, addition, or antagonism) 
may yield insight into the biochemical mechanisms of interaction of the drugs (Pegram et 
al., 1999). 
PRLR antagonist and ER antagonist 
The ability of PRL to stimulate ER expression provides evidence for this 
important physiological crosstalk between these two hormones.  Anti-estrogens are 
compounds that compete with estrogens for binding to the estrogen receptors (ERs).  
Anti-estrogens fail to induce receptor activation, thereby inhibiting hormonal actions on 
target cells. Their ability to interfere with the mitogenic activity of estrogens, anti-
estrogens are widely used for the treatment of various hormone-dependent cancers, either 
alone or in combination.  Tamoxifen (a selective ER modulator, and an ER antagonist) 
has been shown to down-regulate prolactin receptors in breast cancer cells (de Castillo B 
et al., 2004).  A combined regimen using an anti-estrogen (tamoxifen) and an anti-PRL 
secretion drug  (CV 205-502) has been reported to have significantly better clinical results 
in metastatic breast cancer patients as compared with tamoxifen therapy alone (Bontenbal 
M. et al., 1998).  However, this regimen did not take into account that PRL is synthesized 
by human mammary cells and could not block the autocrine/paracrine activity of PRL on 
breast cancer.  Another combination study was tested using tamoxifen with a complete 
PRL blockade that acts at the receptor level.  When anti-PRL (G129R) and tamoxifen 
were applied simultaneously, an additive inhibitory effect on breast cancer cell 
proliferation was observed (Chen et al., 1999) demonstrating the crosstalk between these 
two pathways.   
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anti-HER2 and ER antagonist 
Although there is an inverse relationship between the degree of ER positivity and 
HER-2/neu expression, a significant proportion of human breast cancers are both ER 
positive and overexpress HER-2/neu (Ravdin et al., 1998; McCann et al., 1991; Berry et 
al., 2000).  A large body of literature has demonstrated extensive interactions between the 
ER signaling pathway and growth factor receptor (including HER-2/neu) signaling, both 
in terms of downstream effects as well as regulation of each other’s activity (Argiris et 
al., 2004).  A combination approach using the anti-estrogen, tamoxifen, with an anti-
HER2, Herceptin, resulted in synergistic growth inhibition and enhancement of G0-G1 
cell cycle accumulation. This data demonstrates that the combined inhibition of ER and 
HER-2/neu signaling may be a powerful approach to the treatment of breast cancer. 
However, preclinical data suggest that interactions between the ER and HER2 
signaling pathways might be expected to result in clinical resistance of HER2-positive 
breast cancer to hormone therapy.  It is also possible that women with HER2-positive, 
ER-positive breast cancer could have a worse prognosis with tamoxifen therapy than with 
no therapy due to promotion of the agonist effects of tamoxifen through HER2-stimulated 
signaling (Jones, 2003). 
Herceptin and various other chemotherapy drugs have been tested to see which 
are the most effective and safe.  The most effective and safest combination was found in 
a synergistic interaction of Herceptin plus carboplatin, which is an alkylating agent that 
interferes with the growth of cancer cells, and docetaxel, which damages structures 
involved in cell division.  Aromatase inhibitors, indicated for use in postmenopausal 
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women, act by blocking the formation of estrogen, which fuels the growth of "hormone 
receptor-positive" breast cancers.   
Therefore, understanding the mechanism by which PRL stimulates mitogenesis 
and how it interacts with other factors important in breast cancer may lead to improved 
diagnostic assays and therapeutic approaches complementary to current available 
methods (Schroeder et al., 2002).  Important crosstalk mechanisms, such as those 
between PRL and HER2/neu, may be relevant for breast cancer behavior is important to 
investigate. 
Transgenic models for breast cancer 
Transgenic mice are used to test the effects of externally introduced genes.  They 
have allowed researchers to studying mammalian gene function and regulation on an 
entire organism. Transgenic models are powerful tools used to assess the role of selected 
growth factors and associated signaling pathways in mammary carcinogenesis (Rose-
Hellekant et al., 2003). 
PRL transgenics 
Prolactin transgenic mice were developed to understand the role of PRL on 
mammary gland development in experimental models.  A study by Wennbo et al., 1997 
generated two lines of transgenic mice that systemically express rPRL using the 
metallothionein (Mt) promoter in virgin, female mice.  One line had expressed high 
levels of rPRL (150ng/ml), which is four times higher than normal peak values, and the 
other line expressed rPRL levels in the normal range of endogenous PRL (13ng/ml).  
Both lines of female mice overexpressing the rPRL gene developed malignant mammary 
adenocarcinomas (n=9).  The tumors in the rPRL transgenic mice were not seen until 
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later in life (11-15 months of age).  Cell lines were also established from a tumor from a 
transgenic mouse expressing low serum levels of PRL produced rPRL and expressed 
PRLR.  The mammary tumors that developed in the PRL transgenic mice did not 
metastasize.  It was concluded that the tumor development was caused by the activation 
of the PRLR. 
To model the effects of local mammary production of PRL, Rose-Hellenkant et 
al. 2003 generated virgin, female mice under the control of a mammary selective 
hormonally nonresponsive promoter, neu related lipocalin (NRL).  This promoter was 
useful to study the interaction of factors contributing to mammary carcinoma independent 
of hormonal changes in transgene expression.  In two NRL-PRL transgenic lines 
generated, both lines of female mice lead to the development of mammary lesions and 
ERα positive and ERα negative mammary tumors (Rose-Hellekant et al., 2003).  This 
model provided a system to examine the roles of both local and circulating PRL in 
mammary oncogenesis in a defined transgenic system (Arendt et al., 2006). 
Based on Wennbo's study, PRL transgenic mouse models revealed the pro-
oncogenic effect of PRL over-expression in virgin mammary glands.  To address whether 
PRL tumorigenicity was maintained on differentiated mammary glands, Manhes et al., 
2006 generated mammary specific transgenic mice expressing hPRL under the control of 
the milk whey acidic protein (WAP) promoter.  This promoter directs autocrine hPRL 
over-expression in late gestation throughout lactation.  In this transgenic model, minimal 
levels of transgene expression (2-8ng/ml) were detected in the mammary glands of the 
virgin mice, but expression of mammary hPRL dramatically increased at the end of the 
first pregnancy (180ng/ml).  Overexpression of hPRL led to morphological mammary 
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alterations, lactation defects and eventually to involution failure.  Although some older, 
multiparous females developed benign tumors, none of the mice developed mammary 
carcinomas. 
 HER2/neu transgenics 
 Overexpression and amplification of the neu (c-erbB, ErbB2) proto-oncogene 
have been implicated in the development of aggressive human breast cancer (Guy et al., 
1992).  To assess the effects of the expression of the neu proto-oncogene in the mammary 
gland, Guy et al. established transgenic mice carrying neu under the transcriptional 
control of the mouse mammary tumor virus (MMTV) promoter.  Expression of the neu 
transgene resulted in the appearance of focal mammary adenocarcinomas, which 
eventually metastasized to the lung.  Tumorigenesis in these transgenic lines was 
correlated with elevated expression of the neu transgene and an increase in neu-
associated tyrosine kinase activity (Guy et al., 1992) 
Cyclin D1 proto-oncogene is an important cell cycle regulator of G1 to S- phase 
transition.  Binding of cyclin D1 to its kinase partners, the cyclin dependent kinases 4 and 
6 (CDK4\6) results in the formation of active complexes that phosphorylate the 
retinoblastoma tumor suppressor protein (Rb). Hyper-phosphorylation of Rb results in the 
release of Rb-sequestered E2F transcription factors and the subsequent expression of 
genes required for entry into S-phase. It has been reported that cyclin D1 plays an 
important role in breast cancer formation and that cyclin D1 protein is over expressed in 
over 50% of human mammary carcinomas.  Wang et al. 1994 also demonstrated that 
MMTV-cyclin D1 transgenic mice develop mammary hyperplasia and carcinomas. Yu et 
al. investigated whether the ablation of cyclin D1 protects against breast cancers by 
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crossing cyclin D1 knockout mice with four different strains of breast-cancer-prone 
MMTV-oncogene transgenic mice: Ras, c-neu, c-myc and Wnt-1.  Cyclin D1 knockout 
mice were resistant to mammary cancers induced by the neu and ras oncogene, but not 
the c-myc or Wnt-1 oncogenes.  Cyclin D1 knockout mice revealed that the ras and neu 
oncogene were dependent on cyclin D1 for malignant transformation of mammary 
glands, but not cyclin D2 or cyclin D3. 
 To address the role of cyclin-D1-dependent kinases in transformation of 
HER2/neu, Yang et al. 2004 established a bitransgenic line expressing the MMTV-p16 
and the MMTV-neu transgene.  The expression of p16 tumor suppressor effectively 
blocked the formation of tumors caused by MMTV-neu.  This demonstrated that 
deregulation of the cyclin-dependent kinase partner of cyclin D1 is an essential target of 
ErbB2 (Yang et al., 2004).  It was also demonstrated that MMTV-cyclin D1 transgene 
failed to accelerate tumor formation by erbB2 since cyclin D1 if fully downstream of 
erbB2. 
 These studies have demonstrated that transgenic mice expressing the neu 
oncogene in the mammary epithelium, mammary tumors are formed.  However Neu-
induced tumors were prevented in the breast in the absence of cyclin D1.  If 
overexpression of cyclin D1 is an early event in mammary carcinogenesis and if blocking 
cyclin D1 in fully formed tumors is not effective, then inhibitors of cyclin D1 may be 





Chemoprevention of Human Breast Cancer  
 The failure of conventional chemotherapy against advanced invasive disease 
indicate that new approaches to the control/prevention of breast cancer are critically 
needed (Arun and Hortobagyi, 2002; Greenwald, 2002). Cancer chemoprevention can be 
defined as treatment of carcinogenesis, including cancer prevention, inhibition, or 
reversal (Sporn & Suh 2000; 2001; Steele, 2003).  Chemo preventative agents are drugs, 
vitamins, diet, hormone therapy or any agent that delays the start of cancer, keep it from 
starting, or stop it from coming back.  
The major challenges facing investigators studying chemoprevention of breast 
cancer are to develop alternative preventive therapies that have fewer side effects, and to 
develop drugs that act independently of status (Cuzick, 2000; Arun and Hortobagyi, 
2002; Greenwald, 2002).  Five classes of potential chemoprevention agents are being 
tested and have shown promise in clinical trials. These agents include selective estrogen 
receptor modulators (SERMS) such as tamoxifen, and other hormonal agents; 
nonsteroidal anti-inflammatroy (NSAIDS); calcium compounds; glucocorticoids 
(compounds that are a type of steroid); and retinoids (chemical cousins of vitamin A). 
Despite increasing evidence that hPRL is involved in breast cancer development, 
there are no chemopreventive or chemotherapeutic agents that target the hPRL receptor 
available.   
Overview and rationale of current work 
In this study we use hPRL antagonist (G129R) together with Herceptin to develop 
a more effective approach to block the HER2 signal transduction in breast cancer cells.  
We will determine if G129R and Herceptin combination approach will effectively block 
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HER2 and PRL signaling pathways.  We will also investigate whether the 
autocrine/paracrine effects of hPRL stimulate and G129R blocks overexpressed HER2 
protein phosphorylation via the interaction of JAK2 in breast cancer cells.  Understanding 
the molecular mechanism by which PRL stimulates tumorigenesis and how it interacts 
with other factors are important in breast cancer and help develop new therapeutic 
approaches. 
To investigate the relationship between PRL and HER2/neu in mammary 
tumorigenesis we generated bitransgenic mice co-expressing hPRL or G129R and neu.  
These bitransgenic mice provide a unique model to study the relationship between PRL 
and ErbB2 signaling pathways and possibly gain insight into the molecular mechanisms 
that lead to tumorigenesis in mammary glands.  Comparison of the mammary tumor 
incidence, rate of tumor formation, characterization of mammary gland whole mounts, 
and potential biomarkers will help us to identify the role of hPRL in HER2/neu 
tumorigenesis.   
To conquer this diverse or heterogeneous disease, growing consensus in the field 
is to attack multiple key pathways at once using agents possessing entirely different 
inhibitory mechanisms.  Designing novel combination strategies for each cancer type are 
essential to decrease cancer morbidity or as an effective preventive measure.  In view of 
the prevalence of ErbB2 overexpression in human breast cancer and the ability of local 
mammary PRL to contribute to human breast cancer, it is critical to establish the 
consequences of the interaction between these two pathways in mammary cancer 









Human PRL and G129R used in this study were produced using an E.coli protein 
production system.  BL21 (DE3) cells (Invitrogen) were transformed with pET22b 
plasmids (Novagen; Madison, WI) which contain cDNAs encoding hPRL or G129R.  A 
seed culture was grown overnight at 37oC.  The following day a large-scale LB growth 
culture was prepared and IPTG was added to induce expression of hPRL or G129R.  
Bacteria was collected, resuspended in a solution containing 0.2M NaPO4 pH 8, 10mM 
EDTA, and 0.5% Triton X-100, and lysed using a Sonic Dismembrator.  The inclusion 
bodies were collected and resuspended in 0.2M NaPO4 pH7, 1%v/v beta 
mercaptoethanol, and 8M urea for refolding.  The refolding process consisted of 
dialyzing the protein against decreasing amounts of urea and beta-mercaptoethanol in the 
presence of 20mM Tris HCl, pH 8.0 for three consecutive days.  The protein was then 
purified by a Q-Sepharose anionic exchange column using a FPLC system (Amersham).   
Based on our previous experience, the purity of the products were typically 98% pure, as 
determined by SDS-PAGE and silver staining.  Trastuzumab (HerceptinTM) was kindly 
provided by the Cancer Center of Greenville Hospital System (Greenville, SC).  
Antibodies   
The following primary antibodies were used:  1:1000 dilution of anti-phospho-
HER2/neu for cell lysate (Lab Vision; Fremont, CA); 1:1000 dilution of anti-HER2/neu 
for cell lysate (EMD Biosciences; Darmstadt, Germany); 1:1000 dilution of anti-cyclin 
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D1 (Invitrogen); 1:10,000 dilution of anti-β-actin (Sigma, St. Louis, MO); 1:10,000 
dilution of anti-hPRL (Abcam; Cambridge, MA); 1:1000 dilution of anti-hPRLR (Zymed 
Laboratories; South San Francisco, CA); 1:1000 dilution of anti-phospho-STAT5a/b, 
anti-phospho-STAT3, and a 1:10,000 dilution of anti-β-tubulin (Upstate Biotechnology; 
Lake Placid, NY).  Anti-phospho-Akt 1/2/3; anti-Akt1; anti-phospho-MAPK (Erk1/2); 
MAPK (anti-Erk1); anti-STAT5; anti-phospho-HER2 (for tissue lysate), and anti-HER2 
(for tissue lysate) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA) and 
used at a dilution of 1:1000. The secondary antibodies, goat anti-mouse IgG- and goat 
anti-rabbit IgG-horseradish peroxidase-conjugates were obtained from Bio-Rad 
Laboratories (Hercules, CA) and used at a dilution of 1:2000. 
Plasmid construction and cloning 
 Primers corresponding to hPRL and G129R (with the sequences encoding the 
signal peptide and with and without the stop codon, plus restriction sites for NdeI: 5'- 
CAT ATG AAC ATC AAA GGA TCG -3', NheI 5'- GCT AGC ATG AAC ATC AAA 
GGA -3', NotI 5'- GCG GCC CGC ATG AAC ATC AAA -3', SpeI 5'- ACT AGT TTA 
GCA GTT GTT -3', SpeI  without the stop codon 5' ACT AGT GCA GTT GTT GTT -3', 
XhoI  5'- CTC GAG TTA GCA GTT GTT -3' and XhoI without the stop codon 5'- CTC 
GAG GCA GTT GTT GTT -3') were used to amplify the hPRL and G129R fragment 
from a previous clone in our lab.  
PCR was run on the GeneAmp 9700 (Perkin-Elmer Biosystems, Foster City, CA, 
USA).  hPRL and G129R PCR fragments were ligated into the TA cloning vector pCR2.1 
(Invitrogen, Inc., Carlsbad, CA) using T4 DNA ligase supplied in the kit.  After ligation 
overnight, 1µl of the ligation was transformed in 25µl of TOP10 chemically competent 
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cells (Invitrogen) following manufacture's procedure for transformation.  The 
transformation was then plated on Luria-Bertani (LB) agar plates containing ampicillin 
(500µg/ml) and X-galactosidase (50nM). X-galactosidase was used to blue-white screen 
the colonies for PCR insert where the transformants that contain vector with the insert 
will be a white color whereas the blue colonies will not have the insert.  White colonies 
were picked from plates and grown in LB broth containing Amp (500µg/ml) and allowed 
to grow overnight at 37° with continuous shaking.  The cultures were then subjected to 
isolation of the plasmid DNA using the Qiagen Miniprep kit (Qiagen Corp., USA) 
following manufacture's instructions.  The plasmid DNA was then digested with 
restriction enzymes to check for the proper size of insert in the vector.   
 hPRL and G129R was subcloned into pCR3.1 mammalian expression vector 
(Invitrogen) and pET22b bacterial expression vector (Novagen) with NdeI and XhoI 
restriction sites including the stop codon.  The pCR3.1 vector was used for stable 
transfections and the pET22b vector was used for protein production.   
hPRL and G129R was subcloned into the puCIG mammalian expression vector 
(Chen et al., 1990) and the PMSG mammalian expression vector (Amersham 



































(source: Novagen)  
Fig. 11. Schematic representation of the cloning and expression plasmids.  The 600 




Several human breast cancer cell lines (T-47D, MDA-MB-134, MDA-MB-483, 
BT-474, MCF-7, MDA-MB-453, MDA-MB-468, MDA-MB-436, SKBR-3 and MDA-
MB-231) were purchased from the American Type Culture Collection (ATCC, Rockville, 
MD).   All cell lines were grown in media supplemented with 10µg/ml Gentamicin 
(GIBCO-BRL, Gaithersburg, MD).  T-47D, MDA-MB-483, BT-474 and SKBR-3 cells 
were maintained in phenol-red free RPMI 1640 medium (GIBCO-BRL, Gaithersburg, 
MD) supplemented with 10% fetal bovine serum (FBS; Hyclone Laboratories, Logan 
UT).  MDA-MB-483 cells were supplemented with 0.2mM sodium pyruvate, 2mM 
HEPES buffer and 200 IU insulin (Sigma, St. Louis, MO).  BT-474 cells were 
supplemented with 1mM sodium pyruvate and 10µg/ml insulin. MCF-7 cells were 
maintained in DMEM (GIBCO-BRL, Gaithersburg, MD) supplemented with 10% FBS.  
MDA-MB 134, MDA-MB 453, MDA-MB-468, MDA-MB-436 and MDA-MB-231 cells 
were maintained in Leibovitz L-15 medium.  MDA-MB 453, MDA-MB-436, and MDA-
MB-231 were supplemented with 10% FBS, but the MDA-MB-436 also received 200 IU 
insulin.  MDA-MB-134 were supplemented 20% FBS and MDA-MB-468 were 
supplemented with 15% FBS.  Cell lines (T-47D, MDA-MB-483, BT-474, MCF-7, 
SKBR-3 and MDA-MB-231) were maintained at 37°C in a humidified atmosphere in the 
presence of 5% CO2 and MDA-MB-134, MDA-MB-453, MDA-MB-468, and MDA-MB-
436 were maintained in the absence of CO2. 
MCNeu, an epithelial origin, and N202F3, a fibroblast origin, were isolated from 
a tumor of a MMTV-Neu transgenic mouse.  MCNeu and N202F3 are maintained in 
DMEM medium supplemented with 10% FBS, 10 µg/ml Gentamicin and 1mM sodium 
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pyruvate. L cells, a human fibroblast cell line, were maintained in DMEM medium 
supplemented with 10% FBS and 10 µg/ml Gentamicin. 
Anchorage-dependent cell growth 
Breast cancer cells in exponential growth were harvested by trypsinization and 
seeded at a concentration of 1x104cells/100µl/well into 96-well culture plates in RPMI-
1640 medium supplemented with 10% CSS and 10µg/ml gentamicin.  Cells were 
incubated overnight for attachment.  The medium was then removed and various 
concentrations of hPRL, G129R, Herceptin or combination of the compounds were added 
in serum-deprived RPMI 1640 medium in a volume of 200µl/well.  Compounds were not 
renewed during the entire period of cell exposure and were incubated for an additional 48 
h.  After incubation, the culture medium was removed and replaced with fresh medium 
(100ul/well) and 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium/phenazine methosulfate (MTS/PMS) solution diluted at a 
1:6 ratio (Cell Titer 96 AQueous non-radioactive cell proliferation kit; Promega, Madison 
WI).    The relative viability of the cells was determined by colorimetric measurement of 
the reduction of MTS by the living cells using a Benchmark microplate reader (Bio-Rad).  
Plates were read at 490 nM and all experiments were carried out in triplicate and repeated 
at least four times for each cell line.  Cell viability was calculated as a percentage of 
control treatments. 
Transient and stable transfection 
 A mouse and human epithelial cell line, MCNeu and T-47D and a mouse and 
human fibroblast cell line, N202F3 and L cells were used for transient transfection.  Cells 
were transfected with hPRL cDNA using different plasmids; the pMSG mammalian 
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expression vector with MMTV promoter (source: Amersham Biosciences) and the 
pUCIG mammalian expression vector with MT promoter (source: Chen et al.).  T-47D, 
and BT-474 were used for stable cell transfection using pcDNA3.1 and pCR3.1 plasmids 
containing the G129R or hPRL cDNA respectively. 
The day before transfection, cells were trypsinized and counted. Epithelial cells 
were plated at a density of 1.75 x 105 cells/ml and fibroblasts were plated at a density of 
0.5 x 105 cells/ml in 2 ml of complete growth medium. Cell density was ~50-80% 
confluent on the day of transfection.  For each well of cells to be transfected, 2 µg of 
DNA was diluted in 100 µl of Opti-MEM® I Reduced Serum Medium without serum.  
For each well, 20 µl of Lipofectin® was diluted in 100 µl of Opti-MEM® I Reduced 
Serum Medium without serum and incubated at room temperature for 30-45 min. The 
diluted DNA solution was combined with the diluted Lipofectin® solution and mixed 
gently and incubated for 10-15 min. at room temperature to form DNA-Lipofectin® 
complexes.  Growth medium was removed from cells, washed, replaced with 0.8 ml of 
Opti-MEM® I Reduced Serum Medium without serum combined with the DNA-
Lipofectin® complexes, and mixed gently by rocking the plate back and forth. Cells were 
incubated at 37°C in a CO2 incubator and medium was replaced with 1ml of growth 
medium containing serum 8h post-transfection for transient transfections and with 2ml of 
growth medium containing serum 24h post-transfections for stable transfections. For 
stable transfections, cells were passed into the selective medium (500 µg/ml Geneticin or 
G418 (Invitrogen) 72h post-transfection to select for neo gene expression.  The 
expression levels of the individual cell lines were determined and the cell lines with the 
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high expression levels were expanded.  Transgene expression of hPRL was tested 48 hrs 
after transfection using an IRMA kit. 
Isolation of proteins: SDS PAGE and western blot: 
Immunoprecipitation 
Treatments were performed at 37° in serum starved media and were terminated by 
washing the cells with ice-cold phosphate-buffered saline (PBS) supplemented with 
0.4mM sodium orthovanadate.  The cells were then harvested by scraping in lysis buffer 
(150mM NaCl, 50mM Tris-HCl (pH 8.0), 100mM sodium fluoride, 2mM EDTA, 1mM 
phenylmethylsulfonyl fluoride, 1mM sodium orthovanadate, 5 mg/ml aprotinin and 5 
mg/ml leupeptin) containing 1% (v/v) NP-40 and were kept on ice for 15 min.  Cell 
lysates were centrifuged at 15,000 g for 15 min. at 4°C.  The detergent extracts 
(supernatant) were collected and subjected to immunoprecipitation.  Cell extracts (500-
1000µg) were mixed with 5µg anti-Jak2 (SC-278) or 4µg anti-Neu (SC-284) and 
incubated at 4° for 2 h with continuous agitation.  Protein A-sepharose (GIBCO-BRL, 
Gaithersburg, MD) (50µl) was added and incubated at 4° overnight.  The beads were 
washed four times with lysis buffer and were pelleted by pulse centrifugation (5 seconds 
in the microcentrifuge at 15,000g).  The sepharose beads were resuspended in 40 µl in 6 
x sample buffer and mixed gently. 
Extraction of protein from cells 
Cells were washed with ice cold phosphate buffered saline (PBS) and lysed in 
200µl of lysis buffer [20mM Tris-HCl (pH 7.4), 150mM NaCl, 1mM EDTA (pH 8.0), 
0.25% sodium deoxycholate, 1% Igepal CA630] containing protease inhibitors (1mM 
phenylmethylsulfonyl fluoride, 1µg/ml aprotinin, 1µg/ml leupeptin; and 1mM sodium 
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orthovanadate).  Cells were incubated on an orbital rotator for 10 min. and then the lysate 
was transferred to a 1.5ml eppendorf tube.  Lysates were gently passed through a 21-
gauge needle 5-6 times to shear genomic DNA and then placed on ice for 10-20 min.  
The lysates were cleared by centrifugation for 15 min. at 14,000 rpm. at 4oC.   
Extraction of protein from tissues   
Fresh mammary gland or tumor tissue was excised and frozen immediately on dry 
ice and stored at -80°C until use.  Approximately 100-200 mg of frozen tissue was 
homogenized on ice using a Polytron PT1200 B in 1 mL of tissue homogenate buffer [20 
mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA (pH 8.0), 0.25% sodium 
deoxycholate, 1% Igepal CA630] containing protease inhibitors (1 mM 
phenylmethylsulfonyl fluoride, 50 mM NaF, 1 µg/ml pepstatin, 1 µg/ml aprotinin, 1 
µg/ml leupeptin; and 1 mM sodium orthovanadate).  Tissue homogenates were incubated 
on ice for 20-30 min. and homogenates were cleared by centrifugation for 15 min. at 
14,000 rpm. at 4oC.   
Immunoblot analysis 
Protein content was determined against a standardized control using the 
Coomassie Blue Protein Assay Reagent (Rockford, IL).  Equal amounts of protein were 
heated in SDS sample buffer for 5 min. at 100oC, subjected to electrophoresis on a 10% 
or 4-15% SDS-PAGE (Biorad, Hercules, CA) and then transferred to Hybond 
nitrocellulose membrane (Amersham, Arlington Heights, IL).  Non-specific binding on 
the nitrocellulose membrane was minimized by blocking for 1h at room temperature (RT) 
with TBS-T [25mM Tris-HCL (pH 7.5), 150mM NaCl and 0.05% Tween 20] containing 
5% non-fat dry milk (Biorad, Hercules, CA).  Membranes were then incubated overnight 
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at 4oC in TBS-T with 5% milk with specific primary antibodies at a concentration 
recommended by the manufacturer with constant gentle agitation.  Membranes were 
washed in TBS-T, and then incubated with secondary antibodies for 2 hours at room 
temperature (RT) with constant gentle agitation.  After secondary antibody incubation, 
membranes were thoroughly washed with water for 5 min, TBS-T for 5 min, and water 
again for 5 min. Membranes were developed by enhanced chemiluminescence reagent 
(Amersham) and then exposed to Kodak MR film (Fisher).  Nitrocellulose membranes 
were stripped in stripping buffer (2% (w/v) sodium dodecylsulfate, 62.5 mM Tris-HCl 
pH 6.7, and 100 mM β-mercaptoethanol added fresh) and incubated at 50°C for 30 min 
with rotation.  Membranes were washed 2x for 10 min in TBST at RT and then blocked 
in 5% milk TBST blocking solution for 1h at RT.  Different primary and secondary 
antibodies were used as described. 
Human breast cancer xenografts in nude mice 
Six to eight-week-old, female athymic nude (nu/nu) mice (Jackson Lab, Bar 
Harbor, ME) were inoculated into the mammary fat pad with 7 x 106 T-47D cells per 
100µl.  Mice were implanted with 17β-estradiol tablets (1.7mg/pellet and 60-day release; 
Innovative Research of America; Sarasota, FL).  Tumor measurements were performed 
once or twice per week, and volumes were calculated using the formula use ½ [length 
(mm)] X [width (mm)]2.  Treatment with Herceptin, G129R, a combination of the both, 
or a control was initiated one week after tumor inoculation.  Purified G129R 
(10mg/kg/daily) or Herceptin (10mg/kg/bi-weekly), or a combination of both was 
injected intraperitoneal (i.p.) for 6 weeks.  Control groups were given sterile phosphate 
buffered saline (PBS).  Each group consisted of 6-10 mice. 
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Generation of multiparous MMTVneu transgenic mice 
Homozygous mice expressing rat neu under the control of the mouse mammary 
tumor virus promoter (MMTVneu) were purchased from the Jackson Laboratory (Bar 
Harbor, ME).  Female MMTVneu mice were bred at 5 weeks of age with male 
MMTVneu mice.  The breeding group contained 34 MMTVneu female mice.  To prevent 
litters from overlapping, all surviving pups from each litter were weaned by 30 days of 
age.  All female study mice experienced two cycles of pregnancy and lactation. They 
were palpated for tumors twice weekly through 12 months. 
Generation of bitransgenic mouse models   
MMTVneu female mice were purchased from the Jackson Laboratory (Bar 
Harbor, ME).  Mice expressing either hPRL or G129R under the control of the MT 
promoter  (MT-hPRL, MT-G129R) came from existing FVB transgenic lines generated at 
our facility (18).  The MT promoter is regulated by heavy metal and directs expression of 
the transgene in most tissues including the liver, kidney, spleen, and mammary gland.  
The linear DNA fragment used for microinjection was a 1.4 kilobase (kb) molecule 
located between the KpnI sites in the pUCIG plasmid.   
MMTV-hPRL and MMTV-G129R cDNA were used to generate hPRL and 
G129R transgenic founder mice from the FVB strain (Jackson) by microinjection of 
DNA into the male pronucleus of fertilized mouse eggs as described previously (Chen 
WY, Wright DC, Wagner TE and Kopchick JJ; Proc Natl Acad Sci USA, 1990).  The 
linear DNA fragment used for microinjection was a 3.22-kilobase (kb) molecule located 
between the Hind III sites in pMSG, which includes the MMTV LTR promoter and the 
SV40.  The MMTV promoter directs expression locally in the mammary gland tissue.   
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MT or MMTV-hPRL and MT or MMTV-G129R heterozygotic male mice were 
bred with MMTVneu homozygous females to produce four bitransgenic lines (MT-hPRL/ 
neu; MT-G129R/neu; MMTV-hPRL/neu; and MMTV-G129R/neu).  All offspring were 
heterozygous for MMTVneu and approximately 50% were positive for either hPRL or 
G129R, respectively.  They were palpated for tumors twice weekly through 12 months.  
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Fig. 12. Schematic representation of the mammalian expression plasmids.  The 600 
bp hPRL cDNA was subcloned into the puCIG or pMSG mammalian expression 
plasmids.  The MT-hPRL or MMTV-hPRL cDNA fragment was digested, purified and 
microinjected into fertilized mouse eggs of FVB mice along with the tyrosinase gene, 
following standard protocol.  
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Identification of transgenic mice 
 Transgene screening, DNA:  PCR 
For DNA, approximately 0.5-0.6 cm of tail snip was used to confirm the presence 
of transgene cDNA.  For each 0.5-0.6 cm of tail, 200 µl of Direct PCR Lysis Reagent 
(Viagen Biotech) was added along with 0.1 mg/mL of proteinase K (Invitrogen).  
Eppendorf tubes were incubated at 55° for 3-16h, to ensure complete lysis.  Lysates were 
then incubated at 85° for 45 min. and were cleared by centrifugation for 10 sec.  To 
confirm DNA expression of transgenes, PCR was performed using extracted DNA PCR 
using the primer pairs listed in Table C1.  Glyceraldehyde-3-phosphate dehydrogenase 
(G3PDH) primers were used as an internal control for PCR.  PCR was run on the 
GeneAmp 9700 (Perkin Elmer Biosystems, Foster City, CA).  PCR for hPRL and 
G3PDH used the following parameters: 30 cycles:  1 min.-94°C, 30 sec-94°C, 2 min.-
68°C, 1 min.-68°C, and final hold of 4°C.  For HER2 primers the following parameters 
used were: 30 cycles: 1 min.-94°C, 30 sec-94°C, 1 min.-62°C, 1 min.-72°C, 6 min.-72°C, 
and final hold of 4°C.   
Transgene expression confirmation, mRNA: RT-PCR 
To confirm mRNA expression of transgenes, RNA was extracted from mammary 
gland tissue that had been frozen immediately following excision.  Approximately 50-100 
mg of frozen tissue was homogenized on ice using a Polytron PT1200 motorized 
homogenizer (Polytron; Bad Wildbad, Germany) in 1mL Trizol (Invitrogen; Carlsbad, 
CA) and processed according to the manufacturer’s instructions.  Female bitransgenic 
mice used for this study were confirmed by RT-PCR using the primer pairs listed in 
Table C1.  Glyceraldehyde-3-phosphate dehydrogenase (G3PDH) primers were used as 
 48
an internal control for RT-PCR.  For RT-PCR the parameters used were:  25 cycles: 45 
min.- 48°C, 1 min.-94°C, 30 sec-94°C, 1 min.-62°C, 1 min.-72°C, 6 min.-72°C, and final 
hold of 4°C.   
Transgene expression confirmation, protein: IRMA, ELISA 
The expression level of hPRL (transgene product) from MT-hPRL and MT-
G129R transgenic and bitransgenic lines was quantitated in serum (blood harvested by 
tail vein) using a Coat-A-Count Prolactin Immunoradiometic Assay (IRMA) kit (DPC, 
Inc., Los Angeles, CA) which measures the specific binding affinity between hPRL and 
anti-hPRL.  This immunological assay does not cross-react with endogenous mouse PRL 
(Bernichtein et al. 2003b) and was performed as per the manufacturer’s 
recommendations.  The expression level of hPRL was measured in tissue homogenates, 
using the Active Prolactin ELISA kit (Diagnostic Systems Laboratories; Webster, Texas).  
Approximately 100 mg of fresh mammary gland tissue isolated from the MT and 
MMTV-hPRL and G129R transgenic and bitransgenic lines were homogenized and were 
assayed to quantitate the expression level of hPRL. 
Transgene sequencing confirmation  
Using hPRL primers, hPRL was PCR and RT-PCR amplified from DNA and 
RNA isolated from the tail and mammary gland, respectively, from the MT-hPRL, 
MMTV-hPRL, MT-hPRL/neu and MMTV-hPRL/neu mice.  Reactions were ran on a 1% 
agarose gel for 45 min. at 100V.  The hPRL fragment was gel extracted and purified.  
DNA or cDNA was then ligated into pCR2.1 plasmid (Invitrogen) and plated on 
LB/AMP/IPTG plates.  Colonies were grown up and DNA was extracted and then 
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digested with restriction enzymes to confirm hPRL insert.  DNA was sequenced using 
M13 forward and reverse primers to confirm sequencing. 
Transgenic mouse mammary gland morphological assessment 
 Mammary gland whole mount 
The fourth and fifth inguinal mammary glands of bitransgenic female mice and 
their female littermates were removed at 1, 3, and 6 months of age and used to prepare 
mammary gland whole mounts.  The isolated glands were spread on glass slides and 
fixed overnight in freshly prepared Carnoy’s fixative at room temperature.  The following 
day, the glands were gradually re-hydrated by decreasing the concentration of ethanol.  
Glands were stained with Carmine Alum Stain overnight and were subsequently 
destained and dehydrated by incrementally increasing the concentration of ethanol.  The 
fat pad was cleared with xylene (Sigma) for 30-60 minutes and mounted with Permount 
(Fisher).  Glands were documented via digital photography.  Glands were documented 
via digital photography and Kodak 1D Image Analysis software (Eastman Kodak 
Company’s Molecular Imaging Systems; Rochester, NY) was used to analyze 40x images 
of the whole mounts.  Two researchers working independently evaluated the total 
numbers of side branches, terminal end buds (TEBs), and lobulo-alveolar structures 
within six different one mm2 grids chosen from each animal (n=6 for each transgenic 
group) and the results were combined. 
Immunohistochemistry  
For histological analyses, the fourth and fifth inguinal mammary glands were 
removed from bitransgenic female mice and their female littermates at 1, 3, and 6 months 
of age and fixed with 4% paraformaldehyde before embedding in paraffin. Five-
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micrometer sections of the mammary glands were deparaffinized in xylene for 5 min and 
rehydrated in a graded series of ethanol. For antigen retrieval, slides were brought to 
boiling in trisodium citrate buffer (10 mM trisodium citrate, 0.05% Tween-20; pH 6.0) 
and placed in a 95°C water bath for 30 min, then cooled to room temperature.  
Endogenous peroxidase activity was blocked with a 10-minute hydrogen peroxide 
treatment and non-immune serum was added to prevent non-specific binding.  Primary 
antibodies (2.5µg/mL) were diluted in non-immune serum and slides were incubated 
overnight in a moist chamber at 4° C.  3,3'-diaminobenzidine (DAB) was used as the 
detection reagent.  For detection of Ki67 antigen, a standard kit was used (Novocastra 
Laboratories; Newcastle upon Tyne, England) following the manufacturer’s instructions. 
Sections were lightly counterstained in hematoxylin (Vector Laboratories; Burlingame, 
CA), dehydrated in ethanol, cleared in xylene, and coverslipped with Cytoseal™ 280 
(Richard-Allen Scientific; Kalamazoo, MI).  Stained sections were observed 
microscopically and digitally photographed. To quantify the Ki67 staining intensity, H 
scores were calculated as the summation of the proportion of nuclei stained in each of 
four categories.  The staining intensity (SI) ranged from 0 (no detectable staining) to 3 
(most intense).   
Statistical data analyses 
For Kaplan-Meier survival curves, statistical differences were calculated using the 
Wilcoxon rank sum test.  The results for the number of side branches, number of lobules, 
and Ki67 H-scores were expressed as the mean ± SE accompanied by the indicated 
number of experiments.  Statistical differences between the groups were determined 
using Student's t-test and a two-tailed distribution with unequal variances.  For 
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immunoblots, gel documents were scanned and analyzed using Kodak 1D Image 
Analysis Software.  Densitometric values of protein bands were quantified based on net 
intensity and results for the fold change were expressed as the mean ± SD.  Statistical 
differences between the groups were determined using Student's t-test.  Tumors were 
measured along two major axes with calipers.  Tumor volume was calculated as follows: 
V= 4/3πR12R2 where R1 is radius and R2 is radius 2.  The results were presented as means 
± SE.  Statistical significance, for all in vivo experiments including the cumulative tumor 
volume and tumor weights, were determined using a one-way ANOVA, followed by 
Tukey's Multiple Comparison Test. A value of p<0.05 and p<0.001 was considered 
































Co-expression of PRLR and HER2/Neu in human breast cancer cells 
 
 The expression levels of PRLR, Neu, and phospho-Neu in ten human breast 
cancer cell lines were measured by Western blotting analysis to examine HER2/Neu 
expression with their relative hPRLR levels (Fig. 13).    In six cell lines that express high 
levels of Neu (BT-474. SKBR3, MDA-MB453, MB134, BT483, and T-47D), they were 
found to also express relatively high levels of hPRLR.  The highest HER2 overexpression 
is seen in BT-474, SKBR3, and MDA-MB453 cell lines in decreasing order, which is 
similar to what is reported by others (Cuello et. al., 2001).  There are dual bands that are 
apparent for the Neu and phospho-Neu which sequencing revealed that the upper band 
was a wild-type sequence and the lower band contained a 51-bp in-frame deletion 
(Campbell et al., 2002).  On the other hand, in three cell lines (MDA-MB468, MDA-
MB436, and MDA-MB231) with relatively low hPRLR levels, the HER2 levels are also 















Fig. 13. PRLR and HER2/Neu levels in multiple human breast cancer cells.  Cell 
lysates from ten breast cancer cell lines were isolated to determine the expression level of 
Neu, phospho-Neu and hPRLR levels through western blot analysis. β-actin  shows equal 
loading. 
 
Effect of PRL and combination treatment of G129R and Herceptin on HER2 
phosphorylation 
 
BT-474 cells were cultured in the presence of 0.1 or 1µg/ml of PRL for 5, 10, and 
14 days (Fig. 14).  PRL was able to slightly activate Neu phosphorylation after 5 days.  
After 10 days of incubation with PRL, Neu phosphorylation was maximally activated 
with increasing doses of PRL.  After 14 days, Neu remained phosphorylated, in the 
presence of PRL. In T-47D cells, where constitutive phosphorylated HER2 was non-
detectable, PRL is also able to induce HER2 phosphorylation determined by 
immunoprecipitation assay (Fig. 15).  The exogenous PRL was able to induce tyrosine 
phosphorylation of Neu approximately by 1.5 fold in T-47D cells.  
The effect of PRL on the tyrosine phosphorylation status of Jak2 in T47D cells 
was also examined by immunoprecipitation assay.  PRL was able to stimulate tyrosine 
phosphorylation of Jak2 (Fig. 15), which was similar to what was reported (Yamauchi et 
al., 2000).  
 54
To test the effects of combinational treatments of G129R and Herceptin, BT-474 
cells were used.  There was little change in Neu phosphorylation status in all treatment 
regimens at 1h, and 8h (Fig. 16); this is probably due to the fact that BT-474 cells have 
high levels of constitutively phosphorylated Neu.  After 24h, the inhibitory effects of 
Herceptin on Neu phosphorylation became apparent.   
PRL is able to cross-phosphorylate Neu by 52% compared to the control as 
detected through densitometry after 48h treatment (Fig. 16B).  It is interesting to point 
out that although G129R alone had little effect on hPRL’s stimulatory activity at this time 
point, it exhibited significant additive effect with Herceptin in inhibition of Neu 
phosphorylation both in the absence (-66%) or presence (-70%) of PRL compared to 




















Fig. 14. Extended exposure of PRL on Neu phosphorylation in BT-474 cells. BT-474 
cells were cultured in the presence of hPRL (0.1µg/ml and 1µg/ml) for 5, 10, or 14 days 
as indicated.  Cells were trypsinized and replaced with fresh media or PRL treatment 
every three days.  Cell lysates (30µg) were electrophoresed and immunoblotted with 
















Fig. 15. Effect of PRL on phosphorylation of Jak2 and Neu in T-47D cells.  Serum-
starved T-47D cells were cultured in the presence of hPRL (500ng/ml) for 20 min.  
Detergent extracts (1000µg) were immunoprecipitated with anti-Jak2 (A) and anti-Neu 
(B), respectively.  Eluted proteins were analyzed by immunoblotting with 4G10 (upper 
panels), anti-Jak2 (A, lower panel), and anti-Neu (B, lower panel) as indicated.  The 
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Fig. 16. Effect of G129R and Herceptin on phosphorylation of HER2 in BT-474 
cells. Serum-starved BT-474 cells (A.) were cultured in the presence of G129R (G, 
10µg/ml), Herceptin (H, 10µg/ml), or combination of both (G+H) in the presence or 
absence of hPRL (100ng/ml) for the time indicated. Cell lysates (30µg) were 
electrophoresed and immunoblotted with p-Neu.  The results shown are representative of 
multiple experiments performed under the same conditions.  Beta-actin was shown as 
equal loading control. B. Densitometric scan of p-Neu on BT-474 cells after 48h; 





Synergistic effect of Herceptin and G129R on inhibition of MAPK phosphorylation  
To analyze the synergistic effects of combinational inhibition on MAPK 
phosphorylation to G129R and Herceptin treatment, cellular responses after 15, 30, 60, 
and 90 min. treatments were tested in T-47D cells (Fig. 17A).  After 15 min. treatment, 
Herceptin activated the basal phosphorylation of MAPK in the BT-474 cells, which is 
reported in the literature (3).  Treatment with hPRL, as expected, induced 
phosphorylation of MAPK 15 min. through 90 min.  G129R had little effect on basal 
MAPK activity, but it was able to competitively inhibit hPRL-induced phosphorylation of 
MAPK throughout the whole time course.  The combination of G129R and Herceptin 
was able to synergistically inhibit MAPK phosphorylation induced by hPRL as early as 
30 min., but the best response was seen after 60 min.  Based on densitometry, the 
combination of G129R and Herceptin at 1h was able to synergistically inhibit MAPK 
phosphorylation induced by hPRL (-64%) compared to G129R alone (-19%) or Herceptin 
alone (35%).  The synergistic inhibitory effect of G129R and Herceptin on MAPK 
phosphorylation was prolonged to 48h (data not shown). 
We further tested G129R at a low and high dose in combination with Herceptin 
after 1h treatment (Fig. 17B).  Treatment with hPRL induced strong phosphorylation of 
MAPK by approximately 62% compared to the control (based on densitometry scanning).  
G129R was able to competitively inhibit hPRL-induced phosphorylation of MAPK at a 
low and high dose.  The combination of G129R and Herceptin synergistically inhibited 
MAPK phosphorylation induced by hPRL by -33% at G129R's low dose and by -64% at 
G129R's high compared to Herceptin alone (2%).  The combination of G129R and 
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Herceptin not only competitively inhibited PRL's effects, but together these two drugs 
synergistically inhibited MAPK phosphorylation beyond the basal level. 
The effects of combinational inhibition on MAPK phosphorylation in BT-474 was 
also analyzed after 1 and 48 h (Fig. 18).  After 1 h treatment, Herceptin alone activated 
the phosphorylation of MAPK in the BT-474 cells as seen in the T-47D cells (Fig. 16A).  
Treatment with hPRL and G129R had no effect on MAPK phosphorylation after 1 h.  
However, PRL was able to activate MAPK phosphorylation after 48 h compared to the 
control, and G129R was able to competitively inhibit hPRL-induced phosphorylation of 
MAPK.  Based on densitometry (Fig. 18B), the combination of G129R and Herceptin at 
48 h was able to synergistically inhibit MAPK phosphorylation induced by hPRL (-86%) 
compared to G129R alone (-19%) or Herceptin alone (-75%).  The synergistic inhibitory 
effect of G129R and Herceptin on MAPK phosphorylation was not as dramatic of an 
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Fig. 17. Immunoblot analysis of MAPK activity in T-47D cells after PRL, G129R, 
Herceptin or in combination treatment.  A. T-47D cells were cultured in the presence 
of G129R (G, 10µg/ml), Herceptin (H, 10µg/ml), or combination of both (G+H) in the 
presence or absence of hPRL (100ng/ml) at the times indicated (Panel A) or after 1h 
(Panel B).  Cell lysates were prepared as described in Materials and Methods and 30µg of 
protein were electrophoresed and immunoblotted with proper antibodies as indicated.  
The results shown are representative of multiple experiments performed under the same 
conditions.  B. Densitometric scan of p-MAPK on T-47D cells after 1h; representative of 
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Fig. 18. Immunoblot analysis of MAPK activity in BT-474 after hPRL, G129R, 
Herceptin or in combination treatment. A.  BT-474 cells were cultured in the presence 
of G129R (G, 10µg/ml), Herceptin (H, 10µg/ml), or combination of both (G+H) in the 
presence or absence of hPRL (100ng/ml) for 1h (Panel A) or 48h (Panel B).  Cell lysates 
were prepared as described in Materials and Methods and 30-50 µg of protein were 
electrophoresed and immunoblotted with proper antibodies.  The results shown are 
representative of multiple experiments performed under the same conditions.  MAPK was 
shown as equal loading control.  B. Densitometric scan of p-MAPK on BT-474 cells after 
48h; representative of single experiment.   
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Combination effects of G129R and Herceptin on other intracellular signaling 
pathways 
 
To analyze the effects of combinational inhibition on hPRLR and HER2, the 
phosphorylation status of STAT5a/b, STAT3, and AKT, were also examined.  As shown 
in Fig. 19A, treatment of T-47D cells with hPRL for 1h dramatically induced STAT5a/b 
and STAT3 phosphorylation.  The phosphorylation of STAT5a/b induced by hPRL 
continued for 48h as seen in Fig. 19B.  G129R was able to completely block the 
stimulatory effects of PRL on STAT activation.  As expected, Herceptin had no effect on 
the inhibition of either STAT5a/b or STAT3 phosphorylation.  
Treatment with PRL induced AKT phosphorylation in T-47D after 1h and 
continued for 48h (Fig. 19A & B, respectively).  G129R alone had no effect on Akt 
phosphorylation, but was able to competitively inhibit the effects in the presence of PRL 
back down to basal level.  Exposure to Herceptin decreased Akt phosphorylation in the 
absence or presence of PRL.  As for the combination effects of G129R and Herceptin 
seen in the inhibition of Akt phosphorylation, were most likely due to the effect of 
Herceptin. 
The effects of G129R and Herceptin treatment on STAT5a/b, STAT3, AKT, and 
MAPK phosphorylation were repeated in BT-474 cells (high HER2, but low hPRLR, Fig. 
20).  Despite the fact that BT-474 cells have considerable levels of hPRLR, hPRL had 
little effect on phosphorylation of STATs.  The effects of G129R on AKT 
phosphorylation were also minimal, whereas the effects of Herceptin were apparent after 
1h and remained after 48h.  Herceptin was able to inhibit AKT phosphorylation to a 
greater extent at 48h than at 1h in the absence and presence of hPRL in BT-474 cells.  
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When G129R and Herceptin were combined, results were similar to that of Herceptin 
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Fig. 19. Immunoblot analyses of STAT5a/b, STAT3, and AKT in T-47D cells.  T-
47D cells were cultured in the presence of G129R (G, 10µg/ml), Herceptin (H, 10µg/ml), 
or combination of both (G+H) in the presence or absence of hPRL (100ng/ml) as 
indicated for 1h (Panel A) or 48h (Panel B).  Cell lysates (30µg) of protein were 
electrophoresed and immunoblotted with proper antibodies as indicated.  The results 
shown are representative of multiple experiments performed under the same conditions.  
Beta-actin was shown as equal loading control.  
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Fig. 20. Immunoblot analyses of STAT5a/b, STAT3, and AKT in BT-474.  BT-474 
were cultured in the presence of G129R (G, 10µg/ml), Herceptin (H, 10µg/ml), or 
combination of both (G+H) in the presence or absence of hPRL (100ng/ml) as indicated 
for 1h (Panel A) or 48h (Panel B).  Cell lysates (30µg) of protein were electrophoresed 
and immunoblotted with proper antibodies as indicated.  The results shown are 
representative of multiple experiments performed under the same conditions.  Beta-actin 





Effects of PRL and G129R overexpression on HER2 positive cell proliferation 
  To examine the effects of PRL or its antagonist on cell growth in HER2 and 
PRLR positive cell lines, T-47D and BT-474 cells were transfected with PRL or G129R 
(Fig. 21).  The stable cells were confirmed by RT-PCR and the PCR products were 
further sequence confirmed for either PRL or G129R (data not shown).  Stable cell lines 
with high expression levels of PRL or G129R were selected using an immunoradiometric 
assay (IRMA).  For T-47D cells, two different clones with different expression levels for 
PRL and G129R were tested.  T-47D hPRL A expression was approximately 4ng/ml/48h 
and hPRL B expression 2ng/ml/48h.  Whereas G129R A expression was 120ng/ml/48h 
and G129R B expression was 61ng/ml/48h.  BT-474 cells expressed 11ng/ml/48h of 
hPRL and 41 ng/ml/48h of G129R expression. 
  Using a cell proliferation assay, stable cells and the vector transfected cells as 
control was monitored for cell growth over a five day period.  Cells over-expressing PRL 
slightly increased cell proliferation in both T-47D (Fig. 21A) and BT-474 cells (Fig. 21B) 
depending on the PRL expression level.  G129R stable cells were able to inhibit cell 
growth in both T-47D and BT-474 cell lines.  The higher the expression level of G129R 
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Fig. 21. Effects of PRL and G129R overexpression in HER positive cell 
proliferation.  T-47D (A) and BT-474 (B) cells were transfected with vector, hPRL or 











Effects of PRL, G129R, Herceptin or combinational treatments on anchorage-
dependent cell growth 
 
To study the proliferative and anti-proliferative effects of hPRL, G129R and 
Herceptin, cells were treated with a wide dosing range to determine the EC50 or IC50 of 
each agent.  T-47D breast cancer cells were treated with hPRL for 48 h demonstrating a 
bell shaped curve where 100ng of hPRL was a maximum dose (Fig. 22A).  T-47D cells 
were also treated with a range of doses (0.5µg-50µg) of G129R or Herceptin.  Both 
agents inhibited cell proliferation in a dose dependent manner (Fig. 22 B&C) with their 
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Fig. 22. Dose response of the treatment of PRL, G129R and Herceptin in T-47D 
cells. T-47D cells were treated with increasing doses of hPRL (Panel A), G129R (Panel 
B), and Herceptin (Panel C) respectively for 48 h.  After continuous exposure to each 
agent, MT-PMS colorimetric growth assay was performed.  Results were expressed as % 
of control (cells without treatment) in each experiment.  The mean value and SD of the 
mean value of three or more wells in at least three experiments was reported. 
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To study the anti-proliferative effects of 10µg/ml G129R, 10µg/ml Herceptin, or 
the combination of both agents with or without hPRL (100ng/ml), T-47D (Fig. 23A) and 
BT-474 (Fig. 23B) cells were cultured continuously for 48 h with treatment.  G129R or 
Herceptin alone exhibited an inhibition on cell growth, whereas the combination of the 
two had a slight additive affect both in the presence or absence of hPRL in both cell lines.   
In T-47D cells, G129R inhibited cell proliferation approximately -5%, Herceptin 
inhibited -16% (p<0.01) and the combination demonstrated an additive effect by 
inhibiting cell growth by -23% (p<0.01) compared to the control.  However, when T-47D 
cells were cultured in the presence of 100ng/ml of hPRL, cell viability was increased to 
+8%.  The stimulatory effect of hPRL was reversed with G129R down to -1%, Herceptin 
to -10%.  The combination of both agents significantly inhibited the rate of proliferation 
to -13% (p<0.01) compared to that of the control level.   
Herceptin was more effective in the inhibition of the proliferation of BT-474 cells 
(-33%) (p<0.01) as compared to that of G129R’s (-5%), and the combination approach 
slightly increased to -38% (p<0.01) compared to the control due to the basal level of 
HER2.   This trend of response is also observed when BT-474 cells were cultured in the 
presence of hPRL, the inhibitory effect of Herceptin alone was -40% (p<0.01); whereas 
G129R alone reached -11%; the combination of both had approximately -47% (p<0.01) 
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Fig. 23. Growth response of T-47D and BT-474 cells to G129R, Herceptin or 
combinational treatments.  T-47D (Panel A) and BT-474 cells (Panel B) were 
incubated with G129R (10µg/ml), Herceptin (10µg/ml), or combination of G129R and 
Herceptin in the absence or presence of hPRL (100ng/ml) for 48 h.  After continuous 
exposure to treatment, MT-PMS colorimetric growth assay was performed.  Results were 
expressed as a percentage of control (cells without treatment) in each experiment.  The 
mean value and SD of the mean value of three or more wells in at least three experiments 




Effects of G129R and Herceptin on growth of T-47D and BT-474 human breast 
cancer xenografts in nude mice 
 
 To determine the effects of G129R and Herceptin combinational treatment on 
tumor growth, T-47D and BT-474 cells were inoculated into the mammary fat pad of 
female nude mice.  One week after tumor cell inoculation, purified G129R 
(10mg/kg/daily) or Herceptin (10mg/kg/bi-weekly), or a combination of the two were 
intraperitoneal injected for at least 6 weeks.   
 After six-weeks of treatments, Herceptin was able to inhibit T-47D tumor growth 
by 46%, whereas G129R inhibited tumor growth by 53.3% (p<0.05).  The best response 
was observed in the combination treatment group, in which the tumor growth was 
significantly inhibited by as much as 76.5% (p<0.001) compared to the control group 
(Fig. 24A).  Similar results were apparent in the tumor weights when mice were 
euthanized at the end of the study (Fig. 24B). 
The results from the experiments conducted using BT-474 cells were similar to 
that of from T-47D cells.  Herceptin was able to inhibit BT-474 tumor growth by 62% 
(p<0.05), whereas G129R inhibited tumor growth by 65% (p<0.05).  The combination 
treatment group inhibited tumor growth to a greater extent than single agents alone 





















































































Fig. 24. Effect of G129R and Herceptin on T-47D xenografts in nude mice.  A. T-
47D cells (7 x106) were injected in the mammary fat pad of female nude mice.  One week 
after tumor cell inoculation, purified G129R (10mg/kg/daily) or Herceptin (10mg/kg/bi-
weekly), or a combination of both were injected i.p. for 6 weeks.  Measurements of tumor 
growth were recorded once a week.  B. Effects of G129R and Herceptin on the tumor 
weight of T-47D breast cancer xenografts in nude mice. Each value is a mean ± SD of 6-
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Fig. 25. Effect of G129R and Herceptin on BT-474 xenografts in nude mice.  A. BT-
474 cells (7 x106) were injected in the mammary fat pad of female nude mice.  One week 
after tumor cell inoculation, purified G129R (10mg/kg/daily) or Herceptin (10mg/kg/bi-
weekly), or a combination of both were injected i.p. for 6 weeks.  Measurements of tumor 
growth were recorded once a week.  B. Effects of G129R and Herceptin on the tumor 
weight of BT-474 breast cancer xenografts in nude mice. Each value is a mean ± SD of 6-




Generation of PRL or G129R and HER2 bitransgenic mouse models 
 
The MT- or MMTV-hPRL or MT- or MMTV-G129R single transgenic mice and 
MT-hPRL/neu; MT-G129R/neu; MMTV-hPRL/neu; and MMTV-G129R/neu 
bitransgenic mice were confirmed by transgene expression (Fig. 26).  Expression of the 
transgenes was confirmed by performing PCR on genomic DNA isolated from tail 
biopsies and by RT-PCR using RNA extracted from mammary tissues of the mice.  All 
bitransgenic offspring were positive for the neu transgene and transcript and 
approximately 50% were positive for either hPRL or G129R (Fig. 26A&B).  Based on 
RT-PCR results, it does not appear that there is an interaction between any two pairs of 
transgenes; transcript levels were not affected by co-expression of Neu and hPRL or 
G129R (Fig. 26B).   
  Expression of the MT-hPRL and MT-G129R transgenes were confirmed by 
measuring the levels of hPRL and G129R in the serum of the bitransgenic mice using an 
hPRL IRMA.  Approximately 5-10 ng/ml of hPRL and G129R was detected in the serum 
of the bitransgenic mice, but was undetectable in the serum of the MMTV group.  
Expression of the MT and MMTV hPRL transgenes were confirmed by measuring the 
levels of hPRL in the mammary gland tissue homogenates using a PRL ELISA kit.  
Human PRL expression of the MT-hPRL/neu and the MMTV-hPRL/neu was 
approximately 78 ± 50.2 and 341 ± 237.0 pg/mg protein respectively in the mammary 



























































































Fig. 26. Confirmation of transgenic mice.  Transgene expression was confirmed in 
single and bitransgenic mice by (A) PCR and (B) RT-PCR using primers to amplify 
hPRL, G129R and neu sequences. (A) MT and hPRL primers (1002 bp), MMTV and 
hPRL primers (1203 bp) and neu primers (622 bp) were used for PCR to confirm the 
presence of the transgenes in the DNA; representative of n=2-3 mice.  (B) hPRL and neu 
primers were used for RT-PCR to confirm the transcriptional expression of hPRL and 
neu in the mammary gland; representative of n=2-3 mice. G3PDH was used as an internal 




































Fig. 27. Expression of PRL in mammary gland tissue in PRL bitransgenic mice.  
Approximately 100 mg of fresh mammary gland tissue isolated from the MT-hPRL/neu 
and the MMTV-hPRL/neu bitransgenic lines and their neu littermates were homogenized 
and assayed for hPRL expression using the Active Prolactin ELISA kit. The neu 





























Mammary tumor incidence in bitransgenic mice 
 
To investigate the effect of hPRL and its antagonist, G129R, on Neu-induced 
mammary tumorigenesis, the four lines of bitransgenic mice that co-express neu under 
the MMTV promoter and hPRL or G129R under transcriptional control of either the MT 
or MMTV promoter were monitored for palpable tumors.  The total tumor incidence in 
the MT-hPRL/neu line (30/56, t50=438 days, p<0.005) was significantly lower than their 
neu littermates (34/37, t50=345 days) through 500 days (Fig. 28A).  The total tumor 
incidence for the MMTV-hPRL/neu mice were even more drastically reduced (Fig. 28C) 
with only 2 of 23 developing tumors (p<0.0001) at 385 days of age in comparison to their 
littermates (32/35, t50=215 days).  In contrast, co-expression of G129R with either 
promoter in neu female mice had little effect on overall tumor incidence (Fig. 28B): MT-
G129R/neu mice (49/53, t50=323 days) as well as in (Fig. 28D): MMTV-G129R/neu 
































































































Fig. 28. Effects of PRL or G129R co-expression on Neu-induced tumorigenesis. The 
data are plotted as the percentage of tumor-free animals versus age in days. All hPRL and 
G129R bitransgenic mice are represented by closed circles (●), and all neu littermates are 
represented by open circles (○). (A) MT-PRL/neu mice versus neu littermates. Mann-
Whitney U test, p<0.005.  (B) MT-G129R/neu mice versus neu littermates. p=0.19, n.s. 
(C) MMTV-PRL/neu mice versus neu littermates. p<0.0001.  (D) MMTV-neu/G129R 
















HER2/Neu gene expression levels in the mammary gland 
 Because the transforming potential of the Neu protein is closely correlated with its 
intrinsic tyrosine kinase activity, we were interested in examining Neu tyrosine kinase 
activity and Neu expression levels in the mammary gland derived from the tumor 
resistant line MMTV-PRL/neu mice in comparison to their neu littermates (Fig. 29).  We 
found that Neu expression in MMTV-PRL/neu mice was significantly altered.   From 3 
months (p=0.09) up to 6 month of age (p<0.001), MMTV-PRL/neu bitransgenic mice 
demonstrate non-detectable or significantly reduced levels of Neu gene expression as 
compared to their neu littermates.  However, this difference is not obvious at 
phosphorylated Neu levels among animals of the same genotype in three or six months 




























































Fig. 29. HER2/neu gene expression in mammary glands of PRL bitransgenics and 
their neu littermates. Immunoblot analyses of neu littermates versus MMTV-hPRL/neu 
mammary gland tissue isolated from three and six month old mice probed with the 
indicated antibodies. β-tubulin was used as the loading control. Panel B and C, Graphical 
representation of fold change of phospho Neu and Neu, respectively, based on 
densitometric scans of bands (representative of n=4 mice per group).  Means +/- SD are 










Molecular events in PRL bitransgenic mice 
  To determine the cellular events underlying the interaction between the 
transgenes or responsible for the tumor resistance in PRL bitransgenics, we examined the 
signaling molecules known to link to Her2 related tumorigenesis in the mammary gland. 
At three and six months of age, the MT-hPRL/neu mice displayed significantly lower 
cyclin D1 levels (p<0.05) than their neu littermates (Fig. 30A).  Two distinct molecular 
weight bands were observed for cyclin D1 as observed in other studies (19), with the 
higher molecular mass band corresponding to phosphorylated cyclin D1.  Based on 
densitometry, cyclin D1 levels of three and six month old MT-PRL/neu mice were 
reduced approximately 20% and 40%, respectively (Fig. 30C).   
  The MMTV-PRL bitransgenic mice, on the other hand, exhibited lower cyclin 
D1 levels earlier than the MT-PRL bitransgenic mice (Fig. 31).  The MMTV-hPRL/neu 
mice reduced cyclin D1 levels by more than 50% at one month (p<0.001) and by 
approximately 40% at three months (p<0.05) compared to their neu littermates.  By six 
months of age, the cyclin D1 levels of the MMTV-hPRL/neu mice were not significantly 
different from their neu littermates. 
  Differences were also seen in the MAPK activity between the MT-hPRL/neu 
mice and their neu littermates.  One month old hPRL/neu mice demonstrated a slight 
decrease in MAPK phosphorylation and by three months of age, MAPK phosphorylation 
was significantly decreased by more than half (p<0.05) compared to their littermates (Fig. 
30, B&D).  By six months of age, MAPK phosphorylation levels were indistinguishable 
between the two groups.   
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  Similar differences in the MAPK activity were also seen the MMTV-hPRL/neu 
mice and their neu littermates. There was slightly lower levels of MAPK in one month 
old MMTV-hPRL/neu mice (Fig. 31B), but significantly lower phosphorylated MAPK 
levels was observed at three months old (p<0.05).  By six months of age, the difference 
was not obvious between these two groups.  For both lines of PRL/neu bitransgenic mice, 
the decrease in cyclin D1 and MAPK levels was prominent at three month of age. 
  No detectable differences were found in the phosphorylation or basal levels of 
Akt (Fig. 32A) and STAT5a/b (Fig. 32B) pathways at any age of the MT-PRL/neu mice 
compared to the neu littermates.   There were also no measurable differences seen for Akt 
phosphorylation or expression in the MMTV-PRL/neu mice (Fig. 32C).  As for the STAT 
signaling in the MMTV-PRL/neu, there were however slight differences seen in the basal 
and phosphorylated levels of STAT5a/b signaling (Fig. 32D).  At one and three months 
of age, MMTV-PRL/neu mice demonstrated lower levels of STAT5 expression, but were 
not significantly different based on densitometry (data not shown).  Also at three months 
of age, MMTV-PRL/neu mice induced higher levels of STAT5 phosphorylation, but 












































































Fig. 30. Cyclin D1 and phospho-MAPK levels in MT-hPRL/neu mice.  Immunoblot 
of: (A) cyclin D1 (32/36 kD) and (B) phosphorylated MAPK (42/44 kD) in the mammary 
glands of MT-hPRL/neu mice and their neu littermates at 1, 3, and 6 months of age.  
Densitometric analyses of (C) cyclin D1 and (D) phosphorylated MAPK in the mammary 
glands of MT-hPRL/neu versus neu littermates at 1, 3, and 6 months of age.  Graphical 
representation of fold change based on densitometric scans of bands from mammary 
gland tissue (representative of n=4-6 mice per group).  β-tubulin was used as the loading 
control. Means +/- SD are presented and differences were evaluated using a two-tailed 




































































Fig. 31. Cyclin D1 and phospho-MAPK levels in MMTV-hPRL/neu mice.  
Immunoblot of: (A) cyclin D1 (32/36 kD) and (B) phosphorylated MAPK (42/44 kD) in 
the mammary glands of MMTV-hPRL/neu mice and their neu littermates at 1, 3, and 6 
months of age.  Densitometric analyses of (C) cyclin D1 and (D) phosphorylated MAPK 
in the mammary glands of MMTV-hPRL/neu mice versus neu littermates at 1, 3, and 6 
months of age.  Graphical representation of fold change based on densitometric scans of 
bands from mammary gland tissue (representative of n=4-6 mice per group).  β-tubulin 
was used as the loading control. Means +/- SD are presented and differences were 


























































Fig. 32. AKT and STAT levels in hPRL/neu mice.  Immunoblot of: (A&C) 
phosphorylated Akt (60 kD) and (B&D) phosphorylated Stat5a/b (97 kD) in the 
mammary glands of MT-hPRL/neu (A&B) and MMTV-hPRL/neu (C&D) mice 
respectively and their neu littermates at 1, 3, and 6 months of age.  (representative of 
















Morphological comparison of the mammary gland of PRL bitransgenic mice and 
their littermates 
 
To determine the effects of hPRL on mammary gland development, we analyzed 
mammary gland whole mounts obtained from the hPRL/neu mice and their neu 
littermates. At one month of age, the MT-PRL/neu mice displayed a significant increase 
in bud formation (p<0.001) relative to the neu littermates (Fig. 33H), whereas the 
MMTV-PRL/neu mice displayed a significant decrease in bud formation (Fig. 34H; 
p<0.05).  However, there is no obvious difference in mammary ductal side branching and 
the number of side branches in the MT (Fig. 33) and MMTV-PRL (Fig. 34) bitransgenics 
as compared to their littermates.  TEBs were clearly visible at the tips of the mammary 
ducts in both groups indicating active ductal elongation.   
By three months of age, the lobulo-alveolar structures in the MT-PRL/neu mice 
were developing, and TEBs were much less apparent, indicating a reduction in major 
ductal elongation.  The mammary ducts had extended throughout the fat pad and become 
well organized (Fig. 33B&E).  The primary ducts of the MT-hPRL/neu mice contained 
approximately 4.4 side branches per mm2 (Fig. 33G), representing a significant increase 
in the level of secondary and tertiary branching (p<0.05) in comparison to their neu 
littermates.  A significant increase in the lobulo-alveolar structures was also observed in 
the MT-hPRL/neu mice (p<0.001) in comparison to their littermates (Fig. 33H). 
 At three months of age, the MMTV-PRL/neu mice demonstrated a phenotype 
opposite to what was represented from the MT-PRL/neu mice.  The primary ducts of the 
MMTV-PRL/neu mice contained approximately 3.6 side branches per mm2 (Fig. 34E), 
representing a significant decrease in the level of secondary and tertiary branching 
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(p<0.05).  MMTV-PRL/neu mice also have significantly less lobulo-alveolar structures 
(p<0.001) in comparison to their littermates (Fig. 34H). 
 By six months of age, extensive lobulo-alveolar development had occurred in the 
MT-hPRL/neu mice.  At this stage, the mammary ducts of several MT-hPRL/neu mice 
displayed secretory lobulo-alveolar products in their lumen, superficially resembling 
lactation (data not shown).  The MT-hPRL/neu mice displayed a significant increase in 
numbers of lobulo-alveolar and TEB structures (Fig. 33H; p<0.001), however the number 
of branches per duct did not significantly differ from their littermates, and had slightly 
decreased from the age of three months (Fig. 33G). Simultaneously, the extent of alveolar 
development was significantly decreased in the MMTV-PRL/neu bitransgenics compared 
to their neu littermates by six months of age (Fig. 34H; p<0.001).  This is in contrast to 
the effects seen in the MT-PRL/neu bitransgenic mice, in which there was a significant 
increase in lobular alveolar development relative to littermates.  As for the neu littermates 
for both lines of transgenic mice, they displayed very similar results in respect to the total 


















































































Fig. 33. Mammary glands of MT-hPRL/neu female mice.  The fourth inguinal 
mammary glands were dissected, stained in carmine alum stain and digitally 
photographed. Panels A-F are the mammary glands of neu littermates at 1, 3 and 6 month 
of age (A to C) versus age-matched hPRL/neu mice (D, E, F, respectively, representative 
of n=6 mice/group).  Quantification of morphological features of 1, 3 and 6 month old 
neu littermates versus hPRL/neu mice was compared either by total number of side 
branches per mm2 (panel G) or total number of TEB and lobulo-alveoli per mm2 (panel 
H).   Means +/- SE are presented (n=6 per group) and differences were evaluated using a 






















































































Fig. 34. Mammary glands of MMTV-hPRL/neu female mice.  The fourth inguinal 
mammary glands were dissected, stained in carmine alum stain and digitally 
photographed. Panels A-F are the mammary glands of neu littermates at 1, 3 and 6 month 
of age (A to C) versus age-matched hPRL/neu mice (D, E, F, respectively, representative 
of n=6 mice/group).  Quantification of morphological features of 1, 3 and 6 month old 
neu littermates versus hPRL/neu mice was compared either by total number of side 
branches per mm2 (panel G) or total number of TEB and lobulo-alveoli per mm2 (panel 
H).   Means +/- SE are presented (n=6 per group) and differences were evaluated using a 







Proliferation indices in PRL bitransgenic mice  
  Reduced activation of extracellular signal-regulated kinases is indicative of 
reduced cellular proliferation and transformation. To examine proliferation we 
immunohistochemically detected the Ki67 marker in the mammary glands of mice at 1, 3 
and 6 months of age in the MT-PRL/neu and their littermates. The levels of Ki67 in three 
month old MT-hPRL/neu mice had a significantly lower H-score than their littermates 
(Fig. 35B).  However, both the one month and six month old hPRL/neu mice were not 
significantly different from their littermates (data not shown).  Obvious differences were 
apparent in acinar and lobulo-alveolar features between hPRL/neu mice and their 
littermates (Fig. 35A).  The neu littermates had a more disorganized appearance and 
appeared to have lost the normal polar organization of basal and luminal epithelial cells 
as evidenced by the smaller luminal spaces.  On the other hand, the MT-hPRL/neu mice 






























Fig.  35. Proliferation indices in MT-hPRL/neu mice and their neu littermates.  (A) 
Ki67 detection in paraffin embedded mammary glands from 3 month old neu littermates 
(left panel) and MT-hPRL/neu mice (right panel). Arrowhead indicates brown nuclear 
staining. (B) Graphical representation of Ki67 H scores of neu littermates (n=4) versus 
MT-hPRL/neu mice (n=4). **, p < 0.001. H scores were calculated as the summation of 








Neu phosphorylation levels in the tumors. 
It was reported that the neu transgene is expressed in normal mammary 
epithelium, salivary gland and lung and higher expression was detected in tumor tissue.  
Because the transforming potential of the c-Neu protein is closely correlated with its 
intrinsic tyrosine kinase activity, we were interested in examining Neu tyrosine kinase 
activity in tumor tissue samples derived from the hPRL/neu mice in comparison to their 
neu littermates.  A prominent band representing phosphorylated Neu was observed in 
immunoblots of tumor extracts from neu littermates at 9 month (Fig. 36A&B).  In 
contrast, no comparable phosphorylation of Neu was detected in the tumors that did 
develop of the MT- and MMTV-PRL/neu mice.  Similarly, the tumor tissues of the neu 
littermates reacted to the phospho-Neu antibody through IHC analyses, but the tumor 




















Fig.  36. HER2/Neu phosphorylation levels in tumors, which arise in the PRL 
bitransgenic mice and their neu littermates.  Panel A, immunoblot analyses of neu 
versus MT-hPRL/neu tumor tissue isolated from 9 month old mice probed with the 
indicated antibodies. Panel B, immunoblot analyses of neu versus MMTV-hPRL/neu 
tumor tissue isolated from 9 month old mice probed with the indicated antibodies.  β-
tubulin was used as the loading control.  Panel C, Phosphorylated Neu IHC analyses from 
paraffin embedded tumor tissue from neu littermate (left panel) and MT- hPRL/neu mice 










Prolactin in transformed cells acts as a tumor promoter  
 
One of the most studied female hormones involved in mammary gland biology is 
PRL.  PRL is a polypeptide hormone intimately involved in the regulation of normal 
breast growth, development, and differentiation (Vonderhaar, 1999; Kelly et al., 2002).  
The role of hPRL in breast cancer is still controversial, but most recent studies favor its 
role as a pathological agent in breast cancer with the following evidence.  Studies suggest 
that hPRL acting as an autocrine/paracrine growth factor may be involved in breast 
cancer initiation/development (Ginsburg and Vonderhaar, 1995; Kelly et al., 2002; 
Clevenger et al., 2003).  The importance of hPRL in mammary tumor is supported by 
evidence that: hPRL is produced locally by breast cancer cells (Ginsburg and 
Vonderhaar, 1995; Clevenger and Plank, 1997); hPRL receptor expression is up-
regulated in breast cancers (Reynolds et al., 1997; Touraine et al., 1998); and hPRL acts 
as an anti-apoptotic agent whereas anti-hPRL agents such as the hPRL receptor 
antagonist, G129R, induce apoptosis of the breast cancer cells (Chen et al., 1999).   
The human epidermal growth factor receptor 2 (HER2), also known as ErbB2 
receptor tyrosine kinase, plays an important role in human malignancies (Lee et al., 
2002).  Amplification of the HER2 gene with overexpression of HER2 protein occurs in 
20-30% of primary human invasive breast carcinomas and is correlated with poor 
prognosis (DiGiovanna et al., 2002; Argiris et al., 2004; McKenzie et al., 2004; Witters 
et al., 1997; Merlin et al., 2002; Gilbert et al., 2003; Lu et al., 2004).  The finding that 
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HER2 promotes aggressive breast cancer led to the first rationally designed cancer 
therapeutic, Herceptin (trastuzumab), a recombinant humanized monoclonal antibody 
directed against the HER2 extracellular domain (Nahta et al., 2004).  Treatment with 
Herceptin results in down regulation of receptor expression, internalization of the 
antibody-HER2 complex and a decrease in both the association of HER2 with its 
heterodimeric partners and HER2 tyrosine phosphorylation (Ropero et al., 2004), 
inducing regression of HER2 overexpressing breast cancers.  It has been reported that 
autocrine/paracrine secretion of hPRL in breast cancer is able to phosphorylate HER2 
through activation of JAK2 signaling (Yamauchi et al., 2000).  Clinical data further 
demonstrates a strong correlation between hPRL expression and proliferative and 
metastatic activity in HER2 positive breast cancer patients (Yamauchi et al., 2000).  
Since the oncogenic potential of HER2 largely depends on the state of its tyrosine 
phosphorylation, the finding of co-expression and cross-phosphorylation of HER2 via 
hPRL leads to the notion that in order to effectively block the oncogenic effects of HER2, 
inhibition of the hPRLR should be considered. 
Therefore, to effectively block PRL’s effects as a tumor promoter on HER2 
signaling and its ability to cross-activate HER2, we investigated the potential benefit of a 
combinational therapeutic approach using an anti-hPRLR (G129R) and an anti-HER2 
(Herceptin) for HER2 positive breast cancer as presented in the first section of this 
dissertation.  Two representative breast cancer cell lines, T-47D (high hPRLR, low 
HER2) and BT-474 (high HER2, low hPRLR), were selected as study models.   We were 
able to show that PRL was able to stimulate tyrosine phosphorylation of Jak2 (Fig. 15) in 
agreement with Yamauchi et al., 2000.  PRL was also able to cross-phosphorylate HER2 
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in T-47D cells and BT-474 cells (Fig. 14 & 15, respectively).  Since the oncogenic 
potential of HER2 largely depends on the state of its tyrosine phosphorylation, the 
finding of co-expression and cross-phosphorylation of HER2 via hPRL suggests PRL’s 
role as a tumor promoter in HER2/neu tumorigenesis.  By inhibiting the hPRLR to more 
effectively block HER2 activation, we were able to demonstrate that combination of 
G129R and Herceptin treatment was able to further inhibit the phosphorylation of HER2 
better than that of using Herceptin alone (Fig. 16).  This combined effect of G129R and 
Herceptin demonstrated on inhibition of HER2 phosphorylation may be clinically 
important since the tumorigenic potential is directly linked to the phosphorylation status 
of HER2.  Our finding of Herceptin’s activation of the phosphorylation of MAPK in T-
47D (Fig. 17A) and BT-474 cells (Fig. 18A) is consistent with what has been reported 
regarding Herceptin in the literature (Argiris et al., 2004), which demonstrated Herceptin 
as being a partial HER2 agonist.   
PRL’s role in mitogenesis was also evident when we demonstrated that hPRL 
treatment induced MAP kinase phosphorylation in both T-47D (Fig. 17) and BT-474 
cells (Fig. 18).  This PRL induced activation of MAPK activity was attenuated by the 
addition of G129R similar to what has been reported (Llovera et al., 2000).  Since PRL 
induced phosphorylation of MAPK and MAPK is also a signaling molecule for HER2, 
we tested the effect between G129R and Herceptin.  The combination treatment of 
G129R and Herceptin synergistically reduced levels of hPRL induced MAPK 
phosphorylation to a greater degree as compared to either agent alone, suggesting cross 
talk between the hPRLR and HER2 pathways was mainly through regulation of MAPK.  
PRL was shown to induce MAPK activation in both cases of high and low PRLR level 
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cell lines and using an anti-PRL and anti-HER2 therapeutic can cooperatively work 
together in inhibiting the stimulation effects of PRL on MAPK phosphorylation. 
The phosphorylation status of STAT5a/b, STAT3, and AKT were also used as 
indications of cellular responses to PRL.  Related to STAT signaling, we were able to 
demonstrate that both STAT5a/b and STAT3 was only responsive to hPRL and G129R as 
previously reported (Cataldo et al., 2000), whereas Herceptin had no effect in STAT 
signaling activities in T-47D cells (Fig. 19).  Both STAT3 and STAT5 are involved in 
PRL activation of the cyclin D1 promoter, suggesting at least one target of PRL through 
this pathway could contribute to tumorigenesis (Clevenger et al., 2003).  In BT-474 cells, 
however, there was no STAT response to PRL or G129R treatment, suggesting the 
phosphorylated STATs were somehow dissociated from hPRLR regulation.  Levels and 
activities of the STATs are altered by multiple hormones, growth factors, and signaling 
cascades, pointing to an obvious role they may play in cross-talk with many other agents 
important in mammary carcinogenesis (Clevenger et al., 2003).  Another signaling 
pathway which is activated by HER2 is the phosphatidylinositol 3-kinase (PI3K)/AKT 
cascade (Nahta et al., 2004).  Despite the fact that both T-47D and BT-474 cells exhibited 
a constitutively phosphorylated AKT, hPRL was able to further stimulate the 
phosphorylation status to a certain degree (Fig. 19 & 20).  Phosphorylation of AKT was 
significantly inhibited with the treatment of Herceptin, whereas G129R had minimal 
effects in AKT phosphorylation.  Based on the use of a hPRL antagonist, G129R, in 
combination with anti-HER2, it has been shown that MAPK, JAK/STAT, and AKT 
pathways play a critical role in PRL-induced proliferation of mammary epithelial cells. 
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  Through the production of stable cells (Fig. 21), we demonstrated that 
overexpression of hPRL increased cell proliferation implicating hPRL's activity as a 
tumor promoter in both high and low HER2 expression level cell lines.  The notion that 
PRL acts as a mitogenic cytokine is supported by the suppression of breast cancer cell 
proliferation with a PRL antagonist, G129R.  Overexpression of G129R suppressed or 
retarded cell growth, blocking the proliferative action of endogenous PRL in HER2 
driven human breast cancer cells.  This data supports the idea that PRL plays an 
autocrine-paracrine proliferative role in the mammary gland and thereby may be involved 
in breast tumor progression. 
  The breast cancer cells were also treated with increasing doses of hPRL.  The 
response of the cells exhibited a bell shape curve (Fig. 22) reflecting the sequential 
dimerization mechanism/ self-antagonism for activation as what has been reported (Fuh 
and Wells, 1995).  Both T-47D and BT-474 cells stimulated breast cancer cell growth in 
the presence of PRL and marginally inhibited cell growth in the presence of G129R (Fig. 
23).  T-47D breast cancer cells showed significant resistance to either G129R or 
Herceptin alone with the maximum inhibition response at less than 20%.  In both cell 
lines, an additive inhibitory effect was observed by the combination of G129R and 
Herceptin, insisting that the combination of the two agents were better than single agent 
alone.  One possible explanation for the somewhat refractory responses from these two 
cell lines in terms of proliferation compared to the signaling may be due to the fact that 
these selected cells express extremely high levels of at least one receptor type, which 
imposes a significant challenge for complete blockage of the surface receptors.  T-47D 
cells have more hPRL receptors than other cells lines and to antagonize their growth 
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would require that the antagonist occupy many more receptors at a time (Fuh and Wells, 
1995).  Previous experiments suggest that only a minimal activation of the hPRL 
receptors was needed to signal a maximal response (Ashkenazi et al, 1987; Fuh et al., 
1993).  This observation may also be true for HER2 activation.  However, this argument 
was weakened when the G129R or Herceptin dose reached beyond physiological 
concentrations (50ug/ml) and the inhibitory effects of cell proliferation were still not 
improved.  This leads to an alternative explanation, which points to the presence of 
constitutively activated intracellular signaling pathways in each of the selected cell lines 
(p-MAPK and p-AKT in T-47D and BT-474 cells).  We postulate that high levels of 
phospho-MAPK and phospho-AKT levels play a dominant role in cell proliferation.  
More importantly, these constitutively activated molecules are for some reason 
dissociated (insensitive) from receptor regulation and are therefore responsible for the 
relative refractory state of these cells in growth regulation.  
We further tested the effects of inhibiting the hPRLR and HER2 pathways with 
G129R and Herceptin treatment on the growth of T-47D and BT-474 xenografts in 
athymic nude mice.  After a six-week period of treatments, the Herceptin treated mice 
were able to inhibit T-47D tumor growth by 46%, whereas the G129R treated mice 
inhibited tumor growth by 53.3%.  When treating the mice with Herceptin and G129R 
together, the tumor growth was significantly inhibited by as much as 76.5% (p < 0.01).  
BT-474 cells responded to treatments in a similar fashion as T-47D cells.  Herceptin was 
able to inhibit BT-474 tumor growth by 62%, whereas G129R inhibited tumor growth by 
65%.  The combination treatment group inhibited tumor growth to a greater extent than 
single agents alone (79.1%).  The tumor growth in all treatment groups were significantly 
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inhibited compared to that of control group after six weeks of treatment.  The 
combination of G129R and Herceptin treatment demonstrated the best outcome in 
inhibition of the tumor growth in both T-47D and BT-474 xenografts.   
Taken together, these findings strongly suggest that PRL’s proliferative effect on 
HER2/neu tumorigenesis exemplifies the reasoning for simultaneous blockade of 
different growth factor-driven signal-transduction pathways might result in a more 
significant antitumor effect (Normanno et al., 2002).  Our results provide a rationale for 
the combined treatment of both Herceptin and G129R on breast carcinoma patients 
whose tumors co-express HER2 and hPRLR.  However, caution has to be taken to 
extrapolate the results from cultured breast cancer cell lines when applied to clinical 
settings since each cell line may represent a unique case in terms of its response to 
various stimuli or inhibitors.  It has been reported that interactions between PRL receptor 
and EGFR pathways depend on the physiological state of the cells and that divergent 
results may reflect spurious differences in cell lines, limited sampling of pathways and 
end points, or alternatively, modulation of receptors and available downstream pathways 
by physiological context and/or accumulating neoplastic changes (Arendt et al., 2006). 
In summary of the first section, we have demonstrated that there is significant 
cross talk between hPRLR and HER2 in these two breast cancer cell lines.  Each receptor 
has its preference in utilizing intracellular signaling pathways, at least in the cell lines 
tested, with MAPK being the shared signaling molecule, suggesting its value as a 
potential biomarker for combinational treatment approach.  It is generally accepted that 
breast cancer, or cancer in general, is a mixture of multiple cell populations or a 
heterogeneous disease.  Our data further demonstrates a strong correlation between hPRL 
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expression and proliferative activity in HER2 positive breast cancer cell lines.  Therefore, 
it is crucial to develop effective combinational approaches with multiple targets to 
maximize the therapeutic impact of each individual agent and at the same time reduce the 
potential side effect.   
Early expression of low levels of prolactin has a protective effect on HER2/Neu 
tumorigenesis 
 
The human epidermal growth factor receptor 2 (HER2, ErbB2) plays an important 
role in human malignancies.  Amplification of the HER2 gene with overexpression of 
HER2 protein occurs in approximately 20-30% of primary human invasive breast 
carcinomas and is correlated with poor prognosis (Slamon et al., 1987).  The decisive role 
of HER2 in mammary tumors has been supported by decades of transgenic studies using 
the rat homologue, neu, driven by the mouse mammary tumor virus (MMTV) promoter 
(Guy et al., 1992).  The MMTV-neu mouse is an important preclinical model because it 
recapitulates the development of HER2 positive human breast cancer, characterized by 
over-expression of HER2 protein and tumor aggressiveness (Ren et al., 2004; Davies et 
al., 1999).  Based on the first section, our data suggests the involvement of hPRL in breast 
cancer development via its interaction with HER2/neu oncogene.  To investigate the effect 
of PRL and it's antagonist on HER2/neu-induced mammary tumorigenesis, we generated 
bitransgenic mice co-expressing neu and hPRL or G129R.  These bitransgenic mice 
provide a unique model to study the relationship between PRL and ErbB2 signaling 
pathways that lead to tumorigenesis.   
 In the second section of our study, transgenic hPRL or G129R mice under 
transcriptional control of either the metallothionein (MT) promoter (a systemic expression 
model) or MMTV promoter (a mammary specific expression model) were cross-bred to 
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MMTV-neu resulting in four lines of bitransgenic mice (MT-hPRL/neu; MT-G129R/neu; 
MMTV-hPRL/neu; and MMTV-G129R/neu) as seen in Fig. 28.  To our surprise, co-
expression of low levels of hPRL in MMTV-neu mice drastically reduced the incidence of 
mammary tumors in both the MT-hPRL and MMTV-hPRL/neu bitransgenic lines.  The 
total tumor rate was only 2 out of 36 (5%) in the MMTV-hPRL/neu line and was reduced 
to 30 out of 56 (53%) in the MT-hPRL/neu line.  In contrast, co-expression of G129R in 
MMTV-neu female mice had no significant effect on overall tumor incidence (>90% 
tumor rates after one year which is similar to their MMTV-neu littermates).  Our working 
hypothesis is that this drastic drop in tumor incidence in both hPRL bitransgenic lines is 
due to the transgenic expression of low physiological concentrations of hPRL induced 
early mammary gland differentiation, which were then resistant to the oncogenic insults of 
HER2/neu.   
 Our first attention was on HER2 because the transforming potential of the Neu 
protein is closely correlated with its intrinsic tyrosine kinase activity.  We examined Neu 
tyrosine kinase activity and Neu expression levels in the mammary gland derived from the 
MMTV-PRL/neu mice in comparison to their neu littermates (Fig. 29).  Mammary glands 
from MMTV-hPRL/neu at six months of age, the age when mammary glands from 
transgenic females begin to develop morphological abnormalities, revealed significant 
reduction in HER2 expression.  It has been reported previously that elevated expression of 
neu may be an important step for tumorigenesis (Guy et al., 1992) implicating the role of 
PRL playing a protective effect in neu tumorigenesis by decreasing HER2 gene 
expression.  On the other hand, PRL had no significant effect on phosphorylation of 
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HER2/neu in the bitransgenic mice, unlike in vitro results where PRL displayed an 
induction of HER2/neu phosphorylation. 
 It has been suggested that treatments with protective hormones result in persistent 
changes in the intracellular pathways which mediate proliferative responses to 
carcinogens (Rajkumar et al., 2001; Sivaraman et al., 1998).  Since cross talk between the 
hPRLR and HER2 pathways was demonstrated mainly through regulation of MAPK when 
using an anti-PRL and anti-HER2 therapeutic in combination, we examined the 
expression levels of MAPK and other biomarkers known to relate to hPRL function in the 
mammary gland.  A significant difference in MAPK phosphorylation was observed 
between the MT-hPRL/neu and the MMTV-hPRL/neu mice compared to their neu-
littermates (Fig. 30 & 31, respectively).  MAPK phosphorylation was down regulated at 
three months of age in both lines of hPRL/neu mice, indicating that the mammary glands 
of the bitransgenic mice were not highly proliferative.  The decrease in MAPK 
phosphorylation induced by PRL in both hPRL/neu mice demonstrates PRL as having a 
dual role; here as a tumor suppressor and earlier as a tumor promoter demonstrated 
through induction of MAPK phosphorylation.  The decreased phosphorylated MAPK 
levels at three months are consistent with the finding that the mammary gland tissue of the 
hPRL/neu mice displays a lower proliferative index than their neu littermates at three 
months (Fig. 35).  The proliferative activity of the mammary epithelium varies as a 
function of the degree of lobular differentiation, which, in turn, is often driven by 
estrogens and progesterone as well as other hormones of pregnancy (Russo et al., 2005).   
Thus, the lower proliferative activity in the hPRL/neu mammary tissue reflects the lower 
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phospho MAPK activity and Ki67 staining indicative of a higher degree or extent of 
differentiation.   
 No significant changes were found in the expression levels of STAT5a/b and AKT 
and their phosphorylation status, which suggest that these pathways are probably not 
directly involved in the alteration of the HER2/neu tumorigenesis.  We examined other 
molecular events related to hPRL's suppressed expression of HER2 and mammary tumor 
resistance in the hPRL/neu mouse model such as cyclin D1.  Cyclin D1 expression has 
been shown to be regulated by PRL (Brockman et al., 2002) and has been demonstrated to 
be essential in the process of HER2/Neu-induced tumorigenesis (Yu et al., 2001).   The 
striking dependence of HER2/Neu on cyclin D1 is highlighted by experiments in which 
the cyclin D1 gene was deleted (Yu et al., 2001), mutated (Landis et al., 2006), or a 
cyclin-dependent kinase inhibitor (p16) was overexpressed in MMTV-neu mice (Yang et 
al., 2004).  In all cases, a complete resistance to tumorigenesis was observed when cyclin 
D1 expression or activity was blocked (Yu et al., 2001;  Landis et al., 2006; Yang et al., 
2004).  We found that co-expression of hPRL and neu significantly lowered the cyclin D1 
expression as compared to that of neu littermates at every age examined in both MT-
hPRL/neu and MMTV-hPRL/neu mice (Fig. 30 & 31, respectively).  By one month of age 
in the MMTV-hPRL/neu, there was almost a 60% reduction in cyclin D1 protein levels 
and by six months of age in the MT-hPRL/neu, there was almost a 40% reduction in 
cyclin D1 protein levels in comparison to their neu littermates.   This finding strongly 
suggests that down-regulation of cyclin D1 through prolonged PRL exposure may be a 
key molecular event by which hPRL affords protection against Neu-induced 
tumorigenesis.  It is also possible that the earlier reduction in cyclin D1 levels in the 
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MMTV-hPRL/neu may lead to earlier tumor resistance which was seen later in age in the 
MT-hPRL/neu mice.  Although the observation of reduced cyclin D1 expression in 
hPRL/neu mice offers a logical explanation for the lower tumor incidence, it raises the 
question as to how the prolonged exposure of low levels of hPRL leads to down-
regulation of cyclin D1 expression.  It is interesting to point out that PRL has been 
reported to have short-term stimulatory effects on cyclin D1 expression (Brockman et al., 
2002).  However, it has also been demonstrated that PRL and EGF have no additive 
effects in cyclin D1 activation (Brockman et al., 2002), suggesting that there may be 
distinct regulatory pathways mediated via the PRLR and HER2/neu in terms of net 
epithelial response.  Detailed studies are warranted in the future to dissect the molecular 
components directly involved in cyclin D1 regulation, such as pRB, p16 and p21 in 
response to the activation of the PRLR and EGFR/HER2/neu in hPRL/neu mice.   
 In an effort to identify the morphological features in the mammary glands of 
hPRL/neu mice related to the resistance of HER2/neu tumorigenesis, we analyzed 
mammary gland whole mounts (Fig. 33 & 34).  In the MT-hPRL bitransgenics, as early as 
one month, the structure of the mammary glands of the hPRL/neu mice was more complex 
than that of their neu littermates.  In addition to new ductal growth, the mammary gland of 
the one month old hPRL/neu female mice displayed an increase in alveolar budding 
indicative of early proliferation/differentiation (Fig. 33H).  This phenotype is in good 
agreement with what was observed in young virgin WAP-hPRL transgenic mice (Manhes 
et al., 2006).  By three months of age, the mammary glands from the hPRL/neu mice had 
significantly more branching and the alveoli were more highly differentiated per lobule 
than their neu littermates (Fig. 33G-H).  In contrast, the acinar and lobular structures of 
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neu littermates had a more disorganized appearance at every age examined.  The lobules 
of the neu mice appeared to have lost the normal polar organization of basal and luminal 
epithelial cells as evidenced by the smaller luminal spaces filled with proliferating cells 
(Fig. 35A).  A reduction in luminal cell death has also been observed in mammary 
epithelial cells expressing the HER2/neu oncogene or activated Akt when grown in 3D 
culture.  The disruption of the normal mammary epithelial cell morphology is a hallmark 
of an epithelial to mesenchymal transition (EMT), indicative of transformation in the early 
stages of malignancy (Bundy LM & Sealy L, 2003; Debnath et al., 2003).  In agreement 
with these observations, a recent study by Nouhi et al., (2006) supports the role of PRL in 
suppression of EMT in cultured breast cancer cells.  They found that increasing levels of 
Jak2 led to a reduction in MAPK phosphorylation and the induction of a more 
differentiated epithelial phenotype (Nouhi et al., 2006).   Therefore, it appears that 
expression of hPRL in these MT-hPRL/neu mice induced and maintained extensive 
mammary gland proliferation/differentiation throughout the critical pre-tumor phase, 
which may serve as the key to the resistance of HER2/neu tumorigenesis.  
 However, when we analyzed the whole mounts from the MMTV-PRL bitransgenic 
mice we noticed a decrease in ductal branching and reduction in development of lobulo-
alveolar structures.  According to Manhes et al., 2006, amplification of PRL activity 
during the final stages of mammary differentiation revealed mammary structures that 
tended to be less developed and completely prevented lobulo-alveolar formation.  It may 
be possible that the stages analyzed for whole mount analysis, the differentiation stage 
was prior to the age we examined and the phenotype that was apparent was similar to 
what is characteristic of during involution.  In another study by Arendt et al., 2006, they 
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demonstrated transgenic PRL delayed ductal morphogenesis, perhaps reflecting PRL 
suppression of estrogen-induced ductal proliferation.  This decrease in ductal branching 
and lobulo-alveolar development is representative of the phenotype of whole mounts that 
display a lack of tumor occurrence.  
 A plausible explanation for the drastic reduction in tumor incidence in both MT-
hPRL and MMTV-hPRL/neu bitransgenic lines is that expression of low levels of hPRL 
induced early mammary gland differentiation and that the differentiated mammary glands 
became resistant to the HER2/neu oncogenic insults.  This explanation is supported by 
well-established epidemiological observations that early full-term pregnancy is associated 
with breast cancer risk reduction.  Russo and colleagues have suggested that parity-
associated protective effects are due to the differentiation of target structures during 
pregnancy (Rajkumar et al., 2001; Russo et al., 2005).  Mechanistically, both hormonal 
and genomic models have been put forth to explain pregnancy-induced protection from 
breast cancer.  It is known that PRL plays a decisive role in the stimulation of lobulo-
alveolar proliferation and differentiation and ultimately the promotion of milk production 
(Vonderhaar, 1999; Horseman et al., 1995).  It has also been postulated that 
undifferentiated epithelial cells are targets for carcinogens and are susceptible to 
neoplastic transformation and that parity-induced differentiation results in an epithelial 
cell population no longer susceptible to carcinogenesis (Russo et al., 2005).  This has also 
been demonstrated recently where PRL over-expression in WAP-hPRL mice is not as 
tumorigenic as it is in the Met-PRL and NRL-PRL models, since it over-activates an 
already differentiated gland (Manhes et al, 2006).  Therefore, co-expression of hPRL in 
MMTV-neu mice may have induced early mammary gland differentiation, mimicking the 
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effects of early pregnancy, thus leading to a relatively refractory state of the mammary 
epithelium to the neu oncogene.  Several studies have shown that the mammary glands of 
parous rats have a decreased proliferative ability, a higher capacity to repair DNA, bind 
lower levels of carcinogens, and are more differentiated in comparison to the mammary 
glands of age-matched virgin rats (Rajkumar et al, 2001; Russo et al., 2005).  
 To investigate if the protective effects exerted by hPRL expression were 
mimicking the effects of early pregnancy, we examined a breeding group of MMTV-neu 
female mice (n=34) that had undergone early and multiple pregnancies.  In Appendix A, 
we found that early and multiple pregnancies in MMTV-neu mice had little effect on total 
tumor incidence and the median onset of tumor occurrence compared to that of virgin 
MMTV-neu mice (t50= 189 days versus t50= 205 days, respectively).  These data are 
consistent with those of Jamerson et al. (2003), who reported that the mammary glands of 
pregnant mice were more susceptible to oncogene-mediated transformation when 
expression of the HER2/neu transgene was positively modulated.  It has also been 
reported that transgenic mice expressing oncogenes under steroid and peptide hormone-
responsive promoters exhibit pregnancy-associated mammary tumors or accelerated 
tumorigenesis in parous females, and therefore may be inappropriate models to 
recapitulate the protective effects of pregnancy on breast cancer (Henry et al., 2004).  It is 
possible that the over-expression of a potent oncogene, such as HER2/neu, overrides the 
potential protective effects elicited by early pregnancy.  In fact, the stimulatory effects of 
the pregnancy hormones may act in synergy with constitutively high levels of HER2/neu 
signaling, resulting in an increase in tumorigenicity.  In any event, the drastic reduction in 
breast tumor incidence in our hPRL/neu bitransgenic models suggest a mechanism that is 
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more complex than simply mimicking the protective effects exerted through early 
pregnancy. 
 Despite the similar levels of Neu phosphorylation in the mammary glands of 
hPRL/neu mice and their neu littermates, there was a high level of phosphorylated Neu 
found in the tumors of the neu mice suggesting a link between malignant growth and Neu 
activation.  However, the tumors derived from a small percentage of the hPRL/neu mice 
contain greatly reduced phosphorylated Neu.  The difference in the levels of 
phosphorylated Neu between tumors derived from hPRL/neu and neu littermates provides 
further evidence for the modulation of Neu-induced tumorigenesis by hPRL.  It has been 
suggested that autocrine PRL is able to cross-phosphorylate HER2/neu through interaction 
with Jak2 in human breast cancer (Yamauchi et al., 2000).  Therefore it is possible that 
prolonged exposure to low levels of hPRL led to a constant cross-phosphorylation of Neu 
at a sub-threshold level of tumorigenesis in the hPRL/neu mice.  We further speculate that 
sub-threshold Neu phosphorylation was insufficient to initiate tumorigenesis but was 
effective at desensitizing the Neu activation as indicated by reduced levels of Neu 
phosphorylation, which translated to the lower tumor rate. 
 PRL transgenic mice have been generated to discern the role of PRL in mammary 
tumorigenesis.   In previous reports, overexpression of PRL has been linked to breast 
tumor formation (Wennbo et al., 1997; Rose-Hellekant et al., 2003).  However, in both of 
our MT-PRL and MMTV-PRL mouse models we have not observed a significant increase 
in the incidence of palpable tumors during the two year period of observation (data not 
shown).   One possible explanation for this discrepancy points to the differences in the 
expression levels of the PRL transgene.  In one study, the expression level of MT-rat 
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(r)PRL in female mice ranged upwards to 150 ng/ml level and the mice developed non-
metastatic mammary tumors at high rates (Wennbo et al., 1997).  Similarly, most female 
mice expressing moderate (45 ng/ml) or high (253 ng/ml) levels of the rPRL transgene 
under the control of the hormonally non-responsive neu-related-lipocalin (NRL) promoter 
developed invasive mammary tumors (Rose-Hellekant et al., 2003).  The hPRL transgene 
expression levels in this study were very low (5-10 ng/ml in serum for the MT line and at 
341 pg/mg of tissue extract for the MMTV line).  This is supported by a recent study by 
Manhes et al., 2006 where very low levels of hPRL (2-8ng/ml) were detected in sera of 
virgin hPRL transgenic female and none of the mice developed mammary carcinomas. 
 Another, albeit less likely explanation, is that hPRL was used in this study whereas 
rPRL was used in the others, suggesting a potential functional difference between the 
hormones from two species.  Rat and human PRL share only a 62% amino acid identity 
although it is known that hPRL activates mouse PRLRs as effectively as rPRL (Hwang et 
al., 1972; Utama et al., 2006).  To our knowledge, there is no evidence in the literature 
that hPRL and rPRL play different roles in mouse mammary tumorigenesis.  
 In this study, the extent of the reduction of tumor incidence was also promoter-
specific. MMTV-hPRL/neu mice were resistant to Neu-induced tumorigenesis to a far 
greater extent than that of MT-hPRL/neu mice.  PRLR mRNA is present in the stroma, 
ductal and alveolar epithelium, although the regulation of expression is different between 
the cell types (Rose-Hellekant at al., 2003).  It has been reported that the MT promoter, a 
ubiquitously expressed regulatory element, may be more active in the stroma than 
epithelium within the mammary gland (Joseph et al., 1999).  The differentiating actions of 
PRL have been recently recognized as an important mechanism by which the hormone 
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could prevent progression and metastasis of differentiated, epithelial-like breast cancer 
cells, but not dedifferentiated, mesenchymal-like breast cancer cells (Nouhi et al., 2006).  
Thus, in addition to the mammary gland specificity of the MMTV promoter, the epithelial 
versus stromal preferential expression driven by the two promoters may also contribute to 
the difference in the resistance to the tumorigenesis.  We examined promoter expression 
by transiently over expressing hPRL under the MT and MMTV promoter in human and 
mouse epithelial and stromal cell lines.  However, it was demonstrated that both the MT 
and MMTV promoter demonstrated increased hPRL expression in the epithelial cell lines 
rather than the stromal cell lines (Appendix B).  
 It is noteworthy that co-expression of G129R in MMTV-neu female mice had little 
influence on the breast tumor incidence.  One explanation is that the expression levels of 
G129R in the bitransgenic mice were too low to effectively counteract or change the 
course of HER2/neu driven tumorigenesis.  G129R expression is only at physiological 
concentration (< 20ng/ml); the ideal therapeutic concentration would be at least at 
hundreds ng/ml based upon our experience. Nonetheless, the lack of the protective effects 
in both lines of G129R/neu bitransgenic mice further verifies the specificity of hPRL 
induced resistance to Neu-induced breast tumorigenesis.   
 In summary of the second section, our findings indicate that co-expression of 
hPRL possesses a unique protective role in MMTV-neu female mice through suppressing 
expression of HER2, which lead to reduced proliferative activities such as lower levels of 
MAPK activities and cyclin D1 expression.  This decrease in HER2 expression and 
alterations in molecular events are indicative of the significant change in the tumor 
incidence in these bitransgenic mice.  The finding of reduced tumor incidence in both the 
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MT-hPRL/MMTV-neu and MMTV-hPRL/MMTV-neu lines supports the notion that co-
expression of hPRL renders the mammary gland resistant to the oncogenic effects of Neu.    
Future studies would be to test exogenous application of hPRL in MMTV-neu female 
mice to see if it has effects similar to those seen in the hPRL/neu bitransgenic mice.  The 
key issues to be tested are the timing, concentration, and the duration of the 
administration.  If our assessment is correct, hPRL could potentially become a 
























The data presented demonstrate that hPRL induces tyrosine phosphorylation of 
HER2/Neu and can stimulate mitogenesis in HER2 positive human breast cancer cells 
therefore serving as a tumor promoter.  By using a PRL antagonist, G129R, in 
combination with Herceptin, stimulatory effects of hPRL are competitively inhibited.  
Results further demonstrate that Herceptin and G129R display synergistic inhibitory 
effects on HER2 and MAPK phosphorylation.  Most importantly, the combination 
treatment of Herceptin and G129R markedly inhibited the growth of xenografts in 
athymic mice.   
 Surprisingly, co-expression of low levels of PRL in MMTV-neu female mice 
demonstrated a drastic reduction in tumor incidence in two hPRL/neu bitransgenic lines.  
Suppressed expression of HER2, which lead to lower levels of MAPK activities and 
cyclin D1 expression were strong indications of evidence that support the significant 
change in the tumor incidence in these bitransgenic mice. 
Thus, PRL possesses a dual role in HER2/neu tumorigenesis: as a growth factor in 
transformed cells or as a survival factor when expressed early before tumor formation.  
To improve the outcome of breast cancer therapy, especially for HER2 positive breast 
cancer, G129R should be further evaluated for use together with Herceptin as a 
combinational therapy.  In addition, data from the PRL bitransgenic mice suggests the 







































Kinetics of tumor occurrence of nulliparous vs. early, multiparous MMTVneu 
transgenic mice 
 
Focal mammary tumors of MMTVneu homozygous transgenic first appear at 4 
month of age, with a median incidence of 205 days (50% mice develop first palpable 
tumor at approximately 200 days of age).  It is also reported that 72% of tumor bearing 
mice that live 8 months or longer develop metastatic disease to the lung.  We tested to see 
if early and multiple pregnancies in MMTVneu homozygous transgenic mice decreased 
tumor incidence since one of the risk factors for breast cancer include nulliparity or first 
full-term pregnancy after age 30. 
Female MMTVneu homozygous mice (n=34) were bred at 5 weeks of age with 
male MMTVneu homozygous mice, Fig. A1.  All female study mice experienced two 
cycles of pregnancy and lactation and all surviving pups from each litter were weaned at 
post-partum day 30.  Female mice were palpated for tumors twice weekly through 12 
months.  It was established that median onset of tumor occurrence of MMTVneu 
homozygous mice experiencing early and multiple pregnancies was slightly decreased 
(t50 = 189 days) compared to virgin MMTVneu homozygous mice (t50 = 205 days).  







































Figure A1.  Early, multiparous MMTVneu transgenic mice.  MMTVneu homozygous 
mice (n=34) were bred at 5 weeks of age with male MMTVneu homozygous mice to 
examine the effect of early and multiple pregnancies in MMTVneu female, transgenic 
mice.  The median onset of tumor occurrence of MMTVneu homozygous mice 
experiencing early and multiple pregnancies was slightly decreased (t50 = 189 days) 


























Comparison of transient hPRL expression driven by two promoters 
To investigate if there is a cell type preference (stromal versus epithelial) between 
MMTV and MT promoters in directing gene expression, transient transfections were 
performed.  A mouse (MCNeu) and human (T-47D) epithelial cell line and a mouse 
(N202F3) and human (L-cells) fibroblast cell line was transfected with hPRL cDNA 
under MMTV and MT promoters from the PMSG and puCIG vectors respectively. 
Expression of prolactin was assayed 72 hrs post transfection using an hPRL IRMA kit. In 
the epithelial cells, hPRL expression was expressed 100 fold higher and in the fibroblasts, 
the hPRL expression was approximately 20-30 fold higher under the MT promoter 















































































Figure B1.  hPRL expression driven by two promoters.  MCNeu, mouse (■) and T-
47D, human (□) epithelial cells and N202F3, mouse (■) and L, human (□) fibroblast cells 
were transfected with hPRL cDNA under MMTV and MT promoters. Expression of 




























Table C1. Primers used for PCR and RT-PCR identification of transgenic mice 
 
 
Primers Name Sequences Product (bp)
MT-hPRL/G129R MT for 5’-CAC GCT GCG AAT GGG TTT ACG-3’ (1002)
hPRL rev 5’-CAG GAT GAA CCT GGA TGA CT-3’
MMTV-hPRL/G129R MMTV for 5’-AGA CTC GCC AGA GCT AGA C-3’ (1203)
hPRL rev 5’-CAG GAT GAA CCT GGA TGA CT-3’
hPRL/G129R hPRL for 5’-TGC TGC TGC TGG TGT CAA-3’ (465)
hPRL rev 5’-CAG GAT GAA CCT GGA TGA CT-3’
neu neu for 5’-CGG AAC CCA CAT CAG GCC-3’ (622)
neu rev 5’-TTT CCT GCA GCA GCC TAC GC-3’
G3PDH G3PDH for 5’-ACC ACA GTC CAT GCC ATC AC-3’ (453)
G3PDH rev 5’-TCC ACC ACC CTG TTG CTG TA-3’
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